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the aim of this thesis is to contribute to the evaluation of active surveillance as an 
option for selected men with adenocarcinoma of the prostate. 
Active surveillance (AS) entails an active observation policy for men with presumably 
curable prostate cancer (PCa) at diagnosis. The concept of AS is to avoid unnecessary 
treatment, with its inherent side effects and costs, while preserving the window of 
cure with active surveillance, in these males with PCa. Though it sounds and even feels 
contradictory to delay treatment in a PCa patient, the rationale of AS can be explained 
by several convincing arguments. 
Firstly, PCa has a huge impact on health care systems in western societies. For example: 
9,516 men were diagnosed with PCa in the Netherlands in the year 2006, a fifth of all 
cancers detected [1] and this number is estimated to increase to 12,032 in the year 
2010 [2]. Likewise one in six males born in the USA today will be diagnosed with PCa 
some time during their life [3]. Secondly, prostate cancer screening, apart from other 
possible pitfalls, has to cope with overdiagnosis, i.e. detection of disease that never will 
cause symptoms and thus will not lead to death. In the European Randomized Study 
of Screening for Prostate Cancer (ERSPC), section Rotterdam, it is calculated that just 
over half the cancers detected will extremely unlikely give rise to symptomatic disease 
[4]. Even if only a subset of men with screen detected PCa can be managed on an AS 
policy this would drastically improve the quality of life in individual patients as they will 
have delayed or no side effects of the treatment. Moreover AS could also hugely reduce 
health care costs associated with treatment and recovery.
The key questions in active surveillance thus are:
- Which patients are suitable candidates for an AS policy?
- How can we select these men?
- How to monitor these men in order not to lose the window of cure?
This thesis does not answer all these questions, but it does represent the start of the de-
velopment of an AS policy within the ERSPC, section Rotterdam. The data of this thesis 
are derived from the ERSPC study which was designed to answer the question whether 
screening has an effect on prostate cancer mortality [5]. This thesis, for all clarity, does 
not attempt to answer that question.
First of all background information on the prostate, PCa and PCa screening is essential 
to understand the window of opportunity for AS in selected prostate cancer patients. 
The introduction explains the effects of PSA driven screening on PCa epidemiology 
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like, stage migration, lead-time, and overdiagnosis as well as providing more detailed 
information about the different parameters used in the following chapters.
Chapter 3 is an overview of the different approaches to expectatively treat PCa and, 
summarizes the different selection and monitoring criteria used at the time, ending with 
a policy proposal for AS. It clearly illustrates the absence of universal nomenclature for 
AS at the time of writing. The term watchful waiting was used which is nowadays com-
monly replaced with AS. The goal of this chapter is to illustrate all aspects of the relative 
new approach of AS. It discusses the needs for proper identification of candidates, the 
development of monitoring techniques and trigger mechanisms for the management of 
PCa patients on AS and to stress the difference compared to expectative management 
modalities, which apply palliative treatment to patients when they develop symptoms.
To identify a subgroup of candidates suitable for AS, the outcomes of patients with 
clinically and screen detected prostate cancer are compared in chapter 4. The results 
show the differences in outcomes between both cohorts making patients with screen 
detected PCa, because they have more favourable characteristics at diagnosis and are 
unlikely to die of PCa within the first five years after the diagnosis, more apt candidates 
for an AS policy.
To further enhance selection of patients possibly fit for an AS policy the use of experi-
mental blood tests was investigated. In chapter 5 PSA precursor forms are evaluated as a 
possible future tool to identify candidates for an AS policy with promising results.
The next chapter deals with a part of the monitoring puzzle. Chapter 6 depicts the 
natural course of PSA levels in ERSPC patients currently managed on an AS policy and its 
value as a monitoring tool to trigger deferred treatment is addressed. 
Chapter 2
Introduction
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GoaL
The goal of this thesis is to contribute to the evaluation of active surveillance (AS) as a 
safe strategy in selected men with organ confined prostate cancer (PCa) at diagnosis. To 
investigate the feasibility of an AS policy the key questions in AS were addressed;
-  Who are suitable candidates?
-  How to select and monitor these men?
-  When to treat these patients without compromising the chance of cure?
suMMaRy
Active surveillance (AS) entails an active observation policy for men with localized 
prostate cancer. The concept of AS is to avoid unnecessary treatment, with its inherent 
side-effects and costs, while preserving the window of cure with deferred treatment. 
To explain the rationale of active surveillance in patients with a possible lethal disease 
several aspects will be highlighted:
- anatomy of the prostate and details of prostate specific antigen,
- epidemiology and natural history of prostate cancer (PCa),
- the relative slow natural progression of disease in most cases and,
- the differences between screen- and clinically detected PCa. 
the PRostate
The prostate is vital for reproduction, not for life. The prostate is a male accessory re-
productive exocrine gland and requires testicular function for its development, growth 
and role in reproduction. Its reproductive function is to expel a complex proteolytic 
secretion into the urethra during ejaculation. This ejaculate contains proteases (pros-
tate specific antigen or PSA) the enzyme amylase, semenogelin, minerals (calcium and 
zinc), proteins of unknown function and is rich in acid phosphatase and citric acid. The 
enzymes liquify the semen after ejaculation while the phosphatases and salts modify 
the vaginal environment to enhance sperm mobility, survival and fertilisation chances. 
anatoMy
A normal prostate gland is about the size of a chestnut, weighs 18 grams and measures 
3 cm in length, 4 cm in width and 2 cm in depth [6]. The prostate is located distal from 
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the bladder around the proximal part of the urethra, and has a somewhat conical shape. 
Figure 1 [7]. 
The base (basis prostatæ) is directed upward, and is anteriorly adjacent to the blad-
der neck and posteriorly to the seminal vesicles and the deferential ducts. The urethra 
penetrates the prostate closer to its anterior than its posterior border. The apex (apex 
prostatæ) is directed downward, and is continuous with the striated urethral sfincter. 
The urethra emerges again from a little above and in front of the apex. The posterior 
surface (facies posterior) is flattened from side to side and slightly convex from above 
downward, and lies about 4 cm. from the anus. The prostate is separated from the rec-
tum by its sheath and some loose connective tissue. Near its upper border there is a 
depression through which the two ejaculatory ducts enter the prostate. The posterior 
surfaces sometimes presents a shallow median furrow, which imperfectly separates it 
into a right and a left lateral lobe. These two lobes form the main mass of the gland and 
are directly continuous with each other behind the urethra. The anterior surface (facies 
anterior) is placed about 2 cm. behind the pubic symphysis, from which it is separated 
by a plexus of veins and a quantity of loose fat. The lateral surfaces are prominent, and 
are covered by the anterior portions of the levatores ani muscles, which are separated 
from the gland by a plexus of veins, the lateral division of the dorsal vein complex. The 
cavernosal nerves run posterolateral to the prostate. The prostate is connected to the 
Figure 1. Anatomy of the prostate adapted from [7].
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pubic bone on either side by the puboprostatic ligaments, which together with the 
superior fascia of the urogenital diaphragm and the anterior portions of the levatores 
ani muscles hold the prostate it in its position. 
The prostate gland has been divided into four zones by McNeal [8]. A transition zone, 
a central zone, a peripheral zone and the anterior fibromuscular stroma that separates 
the transition zone from the remaining glandular zones. Clinically the most interesting 
zones are the transitional and the peripheral zone. The transition zone commonly gives 
rise to benign prostatic hyperplasia and approximately 20% of the prostatic adenocar-
cinomas originate in this compartment. The peripheral zone is the preferential site of 
chronic prostatitis and the origin of around 80% of the prostatic adenocarcinomas [6]. 
PRostate sPeCIFIC antIGen (Psa)
PSA is a protease almost exclusively produced by the prostatic ductal and acinar epithe-
lium. The function of PSA is to cleave semenogelin I and II in the seminal coagulum and 
thus to help with the liquefaction of the ejaculate [9]. Its widespread use in urological 
oncology is explained by improving prostate cancer detection rates when combined 
with the physical examination (digital rectal examination) [10]. However PSA is organ 
Figure 2. Zones of the prostate adapted from [6].
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specific and not cancer specific, meaning that an elevation of PSA can be caused by 
several prostatic diseases including prostate cancer [10-14]. 
The PSA molecule consists of 237 amino acids and weighs 33 kDalton. It was first puri-
fied and characterized in 1979 [15]. PSA belongs to the family of human tissue kallikrein 
proteases which digest high-molecular-weight proteins to release bioactive peptides. 
In total 15 tissue kallikrein genes have been identified [16]. PSA, also known as human 
kallikrein 3 (hK3) is formed in the secretory epithelial prostatic cells and secreted into 
the lumen in an inactive form containing a 7 amino acid precursor protein [17]. This 
precursor PSA (pPSA) is effectively removed extracellularly by hK2 and possibly by hK4 
or trypsin and then secreted into the seminal plasma. In males with normal healthy pros-
tates less than one per million PSA molecules enter the peripheral blood circulation [18]. 
Disruption of the basal membrane, i.e. in prostate cancer or, of the normal architecture 
(prostatitis or benign hyperplasia) of the prostate results in an excessive escape of PSA 
into the circulation [19, 20]. 
PSA is found in the peripheral blood circulation in two forms; a complexed and a non-
complexed or free form. 70-90% of the PSA molecules entering the circulation will 
either bind to the protease inhibitor alpha-1 antichymotrypsine to form the PSA-ACT 
complex or form a stable complex with alpha2-macroglobulin [21, 22]. Complexes with 
other protease inhibitors as c protein inhibitor and alpha1-antitrypsin occur in minor 
amounts [23]. Complexed PSA is around 90 kDalton and thus too large to be cleared by 
glomerular filtration and most probably metabolized by the liver [24] with a half-life of 
2.2 to 3.2 days [11, 25]. 
Free PSA (FPSA) constistute 10 to 30% of all the PSA in the circulation and does not 
form complexes with protease inhibitors due to internal cleavages which have rendered 
it catalytically inactive. FPSA has a biexponential clearing phase, with a rapid initial 
half-life rangin from 0.8 to 2.2 hours and a terminal phase ranging 16 to 33 hours and 
is thought to be cleared by the kidneys [26-29]. Clinically used immunoassays detect 
PSA-ACT and FPSA. The ratio of FPSA, thus the %FPSA in PSA might be used to increase 
both the sensitivity and specificity of PSA testing [30-33]. 
FPSA circulates in at least three different forms; precursor PSA, benign PSA and inac-
tive PSA. Discussing all the PSA derivates is beyond the scope of this thesis however, in 
chapter 4 isoforms of FPSA are evaluated and the following section provides background 
information.
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Precursor PSA (pPSA)
The native precursor PSA is the PSA enzyme plus a 7-amino-acid pro-peptide leader. 
Theoretically seven forms of pPSA could be detectable if the precursor amino acids are 
removed one by one ([-7]pPSA, [-6]pPSA, [-5]pPSA etc). Thus far [-7]pPSA, [-5]pPSA, [-4]
pPSA. [-2]pPSA, [-1]pPSA have been detected [34-36]. 
The [-7], [-5]pPSA and to a lesser extend [-4]pPSA are rapidly converted into mature 
active PSA by hK2 and trypsin in vitro [37-39]. The most stable pPSA form, [-2]pPSA, is 
not activated by hK2 or trypsin and appears to correlate more consistently with prostate 
cancer [40]. Typically, all the pPSA forms together constitute one third of the FPSA in 
cancer serum [41]. Precursor PSA forms have only been identified in plasma, never in the 
seminal plasma, suggesting that, in prostate cancer, the impairment of the architecture 
of the prostatic ductal system will result in an enrichment of pPSA forms and will force 
the pPSA forms into the serum [40]. In clinical studies, pPSA forms improved the clinical 
prostate cancer detection rate and have shown a correlation with aggressive cancers 
[42-44]. 
Benign PSA (BPSA)
Another fraction of FPSA is BPSA. BPSA is a degraded form of PSA due to two internal 
cleavages and, as can be seen in figure 3, BPSA is associated with benign prostatic hyper-
plasia (BPH) tissue and prostatic volume and therefore called benign PSA [45-48]. This 
theory is based on the findings that men with an elevated PSA and a prostatic biopsy 
outcome negative for prostate cancer had significantly elevated BPSA levels, and that 
BPSA was predominantly found in the transition zone tisue [45, 49]. Though BPSA might 
not directly be associated with prostate cancer it could be useful to monitor patients on 
BPH related therapies. BPSA, in contrast to pPSA, is found in both seminal plasma and 
in blood [50]. 
Inactive PSA (IPSA)
Inactive or IPSA is the third form of free PSA found in the circulation. IPSA is a group of 
intact, but enzymatically inactive PSA forms that does not form complexes with ACT 
most probably due to internal cleavage at Lys145-Lys146 [51]. Currently no assay can 
selectively detect the IPSA [52], and the clinical value of IPSA remains to be determined. 
However, indirect estimation of the IPSA level by subtracting the sum of the total BPSA 
and pPSA from the FPSA seems to have some relation with prostate cancer. Though 
results of studies evaluating the adjuvant clinical use of pPSA subforms are promising 
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the assays used are still in the research phase and the results should therefore be inter-
preted with caution [44].
PRostate CanCeR ePIDeMIoLoGy
Adenocarcinoma of the prostate, apart from basal cell carcinoma, is currently the most 
frequently diagnosed malignancy in males in Northern America and Western Europe 
including the Netherlands [3, 53]. For example 9,516 men were diagnosed with PCa in 
2006 in the Netherlands, over a fifth of all cancers diagnosed [1]. This number is cal-
culated to increase to 12,032 in the year 2010 [2]. In the United States, on January 1, 
2005 there were approximately 2,106,499 men alive who had a history of PCa, and it is 
estimated that 186,320 men will be diagnosed with and 28,660 men will die of PCa in 
2008 [3]. 
Though the exact aetiology of adenocarcinoma of the prostate remains unknown [54-
56], the incidence of PCa rises with age. In one study 34% of males in their forties dying 
from competing causes had microscopic evidence of PCa [57]. The prevalence of PCa in 
autopsy studies rises to 80% in males aged 80 years or older [58]. Environmental and 
ethnicity factors most likely also play a role as the highest incidence of PCa is found 
in the United States in African Americans and the lowest incidence is found in Asia 
[59]. Though males with a brother or father with PCa have a substantial elevated risk of 
developing PCa, heriditary PCa does not seem to have a more aggressive biology [60]. 
Recent investigations suggest a relation of PCa with inflammation as this is thought to 
incite carciogenesis by causing cell and genome damage, promoting cellular turn over 
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and creating a tissue microenvironment that can enhance cell replication, angiogenesis 
and tissue repair [61]. 
The impact of PCa on males and the health care system is reflected by the observation 
that one in every six males born in the USA today will be diagnosed with PCa some time 
during their life [3]. The lifetime risk of dying from prostate cancer in the USA is currently 
2.8% [62]. In the period before PSA driven screening the lifetime risk of developing PCa 
was around 8% [63], while the lifetime risk of dying of prostate cancer was 3.6% [64]. 
Thus the risk of being diagnosed with prostate cancer increased with time while the 
percentage of males succumbing to the disease slightly diminished. Though this could 
partially be due do new and improved treatment strategies and modalities it is most 
probably the result of PSA driven screening [65-70]. The profound effects of PSA driven 
screening on PCa epidemiology will be addressed later. 
PRostate CanCeR DIaGnosIs
The diagnosis of PCa requires histological evaluation of prostatic tissue. In the clinical 
setting, an arbitrarily defined serum PSA threshold level, or suspicious digital rectal 
examination prompts a prostatic biopsy. The biopsy procedure is performed transrec-
tally and guided by ultrasound. However, PCa can also be found in tissue chips from a 
trans-urethral resection of the prostate or as an incidentaloma in a cystoprostatectomy 
specimen in patients with bladder cancer. 
The Gleason scoring system for PCa is currently the gold standard [71], and has replaced 
other systems such as the MD Anderson grading system [72]. The Gleason scoring 
system is based on architectural acinar and glandular patterns of prostatic tissue and 
cytological features play no role. Figure 4 [71]. A Gleason pattern can range from 1 
(highly differentiated) to 5 (poorly differentiated). The Gleason sum is the sum of the 
most prevalent pattern observed and the second most prevalent pattern. When only 
one pattern is present, the pattern is doubled. The Gleason score can thus range from 2 
(1+1) to 10 (5+5). A higher Gleason score represents more aggressive PCa and a worse 
prognosis [73-77]. In a Gleason sum important information may be lost as it is unclear 
for a sum of seven whether the most prevalent pattern was 4 or 3. This information is 
clinically important since patients with a Gleason sum of 3+4 have a better prognosis 
than those with a Gleason sum of 4+3 [78]. In the ERSPC, section Rotterdam, a Gleason 
pattern of 1 or 2 is no longer assigned on a prostatic biopsy core due to the relatively 
limited amount of tissue available for pathological examination [79, 80]. The minimal 
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Gleason sum in the ERSPC is thus 3+3 = 6. All data in this thesis are derived from the 
ERSPC and scored following protocol [79]. 
CLInICaL staGInG oF PCa
Apart from the histological diagnosis, PCa is also clinically staged. In the ERSPC, the 
clinical stage is based on the 1992 tumour node metastasis (TNM) classification for PCa 
[81]. The TNM classification is determined by the digital rectal examination (DRE), the 
transrectal ultrasound (TRUS) and radiographic studies when indicated. Since 1992 a 
new classification was introduced for patients with non palpable, PSA driven, detected 
PCa, stage T1C, see table 1 [81].
During a DRE the physician palpates the prostate with the index finger which is in-
serted in the rectum. Assessment of the prostate is thus limited to its dorsal side and the 
origin of the vesiculae seminales. 
With a TRUS of the prostate a two dimensional image of the whole prostate can be cre-
ated. PCa cannot always be visualized [82] and it is under discussion whether it should 
be used in staging screen detected PCa [83, 84]. In the ERSPC hypo-echogenic lesions in 
the peripheral zone of the prostate, if visible in both the sagital as the longitudinal plane, 
are assigned the according clinical tumour stage.
Figure 4. Gleason grading system. Adapted from [71].
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natuRaL hIstoRy oF CLInICaLLy DeteCteD PCa
The diagnosis of PCa will usually trigger both patients and physicians to find a way to 
eliminate all cancerous tissue. However PCa, unlike most other malignancies is a slowly 
table 1. 1992 Tumour node classification system for prostate cancer [81].
T0 No pathological evidence of cancer
T1   Clinically invisible/impalpable tumour 
  T1a incidentally <5% of tissue at transurethral contains cancer
  T1b Incidentally >5% of tissue at transurethral contains cancer
  T1c Cancer identified by needle biopsy due to elevated PSA 
T2   Confined within the prostate 
  T2a Cancer in half of the lobe or less 
  T2b Cancer in more than one half of one lobe but not both lobes 
  T2c Cancer involves both lobes
T3   Extraprostate extension
  T3a Extension outside of the prostate on one side 
  T3b Extension outside of the prostate on both sides 
T3c Extension into one or both seminal vesicles
T4   Invasion of other organs
  T4a Invasion of bladder neck and/or rectum 
  T4b Invades of levator muscles and/or fixation to pelvic wall
N   Regional lymph nodes 
Nx Lymph node invasion cannot be assessed
  N0 No lymph node metastasis 
  N1 Metastasis in single lymph node <2 cm in greatest dimension 
  N2 Metastasis in single lymph node >2cm but <5 cm
  N3 Metastasis in regional lymph node, either multiple or >5 cm
M   Systemic spread 
Mx Metastasis cannot be assessed
  M0 No distant metastasis 
  M1 Distant Metastasis
M1a   non-regional lymphnodes
M1b   bone metastasis
M1c   metastasis to other site.
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progressive disease in most cases. The relatively protracted natural course of PCa can 
be estimated by using prognostic tables such as those created by Albertsen et al. [85]. 
Figure 5 [85] shows the cumulative disease specific mortality (black band), mortality due 
to other causes (grey middle band) and the overall survival (white lower band) up to 20 
years after diagnosis of 767 males stratified for age and Gleason Score at diagnosis.
All men in this study had clinically localized disease and received palliative treatment 
when developing symptoms. The males were diagnosed between 1971 and 1984 and 
were aged 55 to 74 years at diagnosis. Median follow-up is 24 years. Diagnosis was made 
without the use of PSA testing and was mainly based on transurethral resection mate-
rial (60%) and needle biopsy findings (26%). When looking at the patients with well-
differentiated PCa, indicated by a Gleason score of two to five, two to sixteen percent 
died of PCa after 20 years, while 55 to 95% did die of other causes. In the patients with 
a moderate to poorly differentiated PCa, i.e. a Gleason score of seven and higher, the 
percentage of males dying from PCa increases, though in the older age groups 40-60% 
will die of other causes. Another study monitored 223 patients with clinically diagnosed 
organ confined PCa without evidence of disseminated disease on an expectative policy 
with palliative hormonal therapy [86]. The mean follow-up of this study was 21 years. Of 
the 148 patients with grade 1 disease, 14 (9%) died of PCa while 118 (80%) died of other 
causes. In comparison: all nine patients with grade 3 died and five (56%) of them from 
PCa. Grade 1 PCa can be compared to a Gleason score of 3+3 or less, while grade 3 PCa 
measures up to a Gleason sore of 4+4 or higher. Moreover, 80% of the patients in this 
study had a repeat biopsy resulting in a grade change in only 31 patients (17%) resulting 
in a less favourable differentiation for 24 males. None of the patients diagnosed with 
clinically organ confined disease showed dedifferentiation over time. Grade did only 
change for patients diagnosed by TURP (in 73%) or after a prostatectomy (92%). Both 
these reports indicate that patients with favourable disease are unlikely to die of PCa 
and that dedifferentiation of PCa is rare. Moreover, even clinically diagnosed patients 
with poorly differentiated PCa can die of competing causes especially when they are 
diagnosed after 70 years of age. 
PRostate CanCeR sCReenInG anD the eRsPC, seCtIon RotteRDaM
The goal of the ERSPC is to show or exclude a 20% decrease in PCa mortality based 
on PSA screening of asymptomatic individuals [5]. Ideally, advancing the diagnosis by 
screening detects PCa at an earlier stage and combined with timely treatment this offers 
a better hope of cure [87]. 
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Figure 5 shows the cumulative disease specific mortality (black band), mortality due to other causes 
(grey middle band) and the overall survival (white lower band) up to 20 years after diagnosis of 767 males 
stratified for age and Gleason Score at diagnosis. Adapted from [85].
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The ERSPC is a multi-centre randomized controlled trial with 267,994 men participat-
ing in eight different European countries. Pilot studies started in 1993. Of the 42,376 
men aged 55-74 years, from the ERSPC, section Rotterdam 21,166 participants were 
allocated to the intervention arm. After initial protocol changes these men are, since 
1997 invited for a PSA test every four years. A PSA level of 3.0 ng/mL or higher prompts 
a TRUS and TRUS-guided lateral sextant biopsy of the prostate. Detailed descriptions of 
the screenprotocol and results are provided in the following chapters of this thesis and 
in a supplement of the British Journal of Urology International [88]. 
Though long-term natural history data of patients diagnosed in the PSA era are not yet 
mature, the introduction of PSA as a test for PCa screening has drastically changed the 
epidemiology of prostate cancer [65, 67, 89, 90]. Recent studies provide growing evi-
dence for a PSA induced risk migration towards more favourable PCa characteristics at 
diagnosis [67-69, 91]. A favourable shift of prognostic factors is also documented within 
the ERSPC, section Rotterdam [92]. This risk factor migration can be explained by effects 
of PSA driven PCa screening, namely lead-time and length-time. 
Lead-time is the time gained by forwarding the diagnosis with a screen test. Figure 6 
[93]. If forwarding the diagnosis of PCa does not lead to an improvement of survival, a 
lead-time bias is generated. In all screen studies comparisons with unscreened cohorts 
should be adjusted for lead-time.
Lenght-time bias reflects the effect that slow growing cancers are more likely to be 
detected in a screening program, as they remain longer in the preclinical detectable 
phase than fast growing tumours. Figure 7. A relative overrepresentation of these slow 
growing and probably favourable prognostic PCa positively biases the survival results, 
especially if fast growing aggressive PCa are not detected by the screening tools or in 
the screen interval of PCa screening studies.
Preliminary estimates for lead-time in both hypothetical cohorts and prospective ran-
domized screening studies for the detection of PCa range from 5-12 years, depending 
on the definition used [4, 94-98]. Lead-time is presumably shorter for aggressive cancers 
and older males while it is longer for less aggresssive cancers and younger patients. The 
mean lead-time for the ERSPC, Rotterdam, using several 4 year interval screen rounds in 
males aged 55 to 75 years old is approximately 10.3 years [4]. Thus the diagnosis PCa is 
made about 10 years earlier with PSA driven screening in the ERSPC section Rotterdam 
when compared to a clinically detectable disease.
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Lead-time bias
Onset of 
disease
Screen
detectable
Clinical 
disease
Death by 
disease
Lead-timeTime
Effective screening reduces disease specific mortality
Lead-time and effective screening
Lead-time bias
Figure 6. Time is depicted as the dark line, the dotted lines represent the onset of the disease, the time 
at which the disease is screen or clinically detectable and time of disease specific mortality. Lead-time 
is the  time gained by forwarding the diagnosis with a screen test. Screening is effective if subsequent 
treatment postpones or even eliminates disease specific mortality. Adapted from [93].
Length-time bias
Tumour size
Time
Preclinical 
detection
A
B
C
Overrepresentation of  
cancers with a long 
preclinical phase
Figure 7. The y axis depicts tumor size, the x axis time. Smaller tumors can be detected earlier, at a 
preclinical stage, with screening. Fast growing tumors (A) are relatively short and slowly growing tumors 
(C) relatively long in the preclinical detection phase. At any point in time there will thus be a larger 
proportion of slowly growing tumors compared to fast growing tumors. The overrepresentation of these 
slowly progressive cancers in a screen cohort can cause a length-time bias. Adapted from [93].
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Overdiagnosis
While the goal of screening for cancer is to detect the disease at an early stage to 
improve survival, it will also detect asymptomatic PCa that would never have been 
detected clinically if PSA had not been used as a screening test [99]. These cancers could 
be categorized as overdetected or clinically insignificant. The definition of overdetection 
used in most studies is the proportion of cancers that would not have been diagnosed 
during lifetime, in the absence of screening. Calculations of overdetection range from 24 
to 93%, obviously increasing with age and depending of the definition used [4, 95, 97, 
100]. The calculated overdetection rate for multiple four year screen intervals with the 
ERPSC algorithm in Rotterdam is estimated at 54% [4]. This means that more than half of 
the patients diagnosed with PCa would have never developed symptoms of PCa if the 
disease had not been detected by PSA screening. Another study based on population 
based PCa screening, as indicated by medical claims and disease incidence reported 
by cancer registries, showed a calculated age adjusted lead-time of 4.5 years with an 
overdetection rate of 34% [101]. The lower lead-time and overdetection rate can be 
explained by the different study populations, i.e. a screen versus a clinical cohort, but 
also by the fact that in the latter study a PSA cut-off of 4.0 ng/mL was used compared to 
the ERSPC cut-off of 3.0 ng/mL.
Men with overdiagnosed PCa are ideal candidates for an active surveillance strategy 
as PCa treatment with curative intent is not without morbidity and even mortality. Or 
more explicitly, the only treatment effects overdiagnosed patients can experience are 
side-effects, as overtreatment per definition has a 100% cure rate. Moreover, treatment 
of these clinically insignificant cancers will favourably bias the disease specific survival 
after radical treatment (length-time bias).
PRostate CanCeR tReatMent wIth CuRatIVe Intent
Males diagnosed with organ confined PCa (clinical TNM stage ≤ T2) have three curative 
treatment options: 
- surgical removal (laparoscopic or open) of the prostate, 
- destruction of all PCa tissue by radiation therapy, or 
- an active surveillance policy with either option as deferred treatment. 
Most patients and the majority of the physicians will instinctively prefer option 1 or 2; 
immediate eradication of all cancerous tissue. This line of thought is further fuelled by 
the current impressive ten year disease specific survival rates of up to 99% for organ 
confined prostate cancer immediately treated with curative intent [91, 102, 103]. Long-
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term survival rates of patients with well differentiated organ confined disease treated 
in the pre PSA era (ranging from 90 to 94%) show no clear survival benefit for patients 
treated with either treatment modality with curative intent or with delayed palliative 
treatment [104-107]. 
Up to day, only one study prospectively compared open radical prostatectomy (RP) and 
expective management. In 2002, prospective randomised data of 695 clinically detected 
patients men showed that the disease specific survival was statistically significantly bet-
ter for the men treated with RP compared to patients with expective therapy and delayed 
endocrine therapy. However seventeen patients needed to be treated to save one male 
from PCa death, at a median follow-up of 6.2 years. The overall survival did not differ 
between groups [108]. This report was recently updated and at a median follow-up of 
almost 11 years 47 patients in the RP arm (13.5%) and 68 in the expectative therapy arm 
(19.5%) died of PCa. The difference was again statistically significant and the absolute 
risk reduction of 5.4% shows that 19 patients need to be treated to prevent one prostate 
cancer death [109]. In a subgroup analysis it was shown that overall mortality, PCa mor-
tality and the risk of developing metastasized disease was only statistically significantly 
reduced in patients younger than 65 years of age at diagnosis and not present the older 
men. However, these data should not easily be extrapolated to the current screen era 
with its risk migration towards more favourable PCa characteristics at diagnosis, and 
associated lead- and length-time [109, 110]. 
For example, in the study of Holmberg et al. [108], 12% of the men had stage T1C 
disease, 60% had a Gleason sum of 6 or lower, and 47% had a PSA level of 10 ng/mL or 
higher. In the first round of the ERSPC Rotterdam 35% of men had T1C disease which in-
creased to 60% in the second screen [92]. Likewise the percentage of men with a biopsy 
Gleason score of 3+3 or lower or PSA level of 10 ng/mL or lower increased from 62% to 
78% and respectively 68% to 93%. Still, apart from lead- and length-time differences, a 
third point can be made: a conservative management with delayed hormonal therapy is 
not the same as active surveillance as used in this thesis [111]. 
Surgical removal of the prostate, a radical prostatectomy (RP), is not without morbidity. 
Due to the anatomical position of the prostate deep in the pelvis, its close relations with 
the bladder, blood vessels, nerve bundles, external sphincter and the need to reconnect 
the bladderneck to the urethra, side-effects of this procedure are not uncommon. Most 
reported long-term side-effects after radical surgery are incontinence and erectile dys-
function [112-114], though uncommon peri-operative mortality does occur in around 
0.2% [115]. Comparing laparoscopic and open radical prostatectomy at a single institu-
tion it was shown that 35% in the laparoscopic RP group versus 15% of the patients in 
the open RP group still had urinary incontinence after 2 years. Continence was defined 
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by not experiencing leakage of urine or the absence of using protective pads, by self 
administered patient questionaires [116]. 
Likewise, external beam radiotherapy, or radioactive prostatic seed implants (brachy-
therapy) will not only affect the tumour but also damage healthy surrounding tissue like 
the bowel, the bladder and the nerve bundles resulting in corresponding side-effects. 
Even mortality, though uncommon, occurs in 0.3% of patients within 30 days after radia-
tion therapy [117]. 
The five year results of the prostate cancer outcomes study show that 14 to 16% of 
patients were incontinent after RP compared to 4% after external beam radiation 
therapy (EBRT) [118]. Likewise, 79.3% of the patients had erectile dysfunction after 
a RP compared to 63.5% of the EBRT group, but patients with EBRT had more bowel 
complaints than patients treated with a RP. This report did not compare side-effects with 
patients who did not receive treatment. Steineck et al. [119] looked at the quality of life 
of patients with organ confined disease randomized between RP and deferred palliative 
treatment. They found that 49% of the patients after a RP had urinary leakage after four 
years compared to 21% for patients with deferred palliative treatment. The figures for 
erectile dysfunction were 80% for the RP group versus 45%. The large variation of these 
numbers between the reports can be explained by the different definitions used but are 
useful to illustrate that curative treatment for prostate cancer can have serious long-
term side-effects.
Some patients are clearly willing to cope with these side-effects or reduced quality of 
life especially if the treatment prolongs life. However, currently no data of completed 
randomized clinical trials, in the PSA era, comparing treatment modalities are present to 
show a survival benefit of any strategy in patients with well differentiated disease, but 
trials have been initiated and are starting to compare different treatments for localized 
prostate cancer which include screen detected PCa cases [110, 120, 121]. More detailed 
information is provided in the general discussion.
aCtIVe suRVeILLanCe
Active surveillance entails a pro-active observation policy for men with localized prostate 
cancer, while reserving the possibility of deferred curative treatment. The rationale of AS 
is to avoid unnecessary treatment, with its inherent side-effects and costs in patients 
with PCa, who are not likely to progress to clinical disease during their lifetime, while 
offering these selected patients a possible cure at a later time. 
Introduction 31
2
AS thus clearly differs from regimens that provide delayed palliative treatment in pre-
viously untreated males. These regimens will be called expectant management (EM), 
because with palliative treatment there is no intention to cure. At the start of this thesis 
no consensus had yet been reached for the nomenclature for both types of conservative 
management in the literature and in the original publications watchful waiting was used 
[108, 122-125]. However, nowadays active surveillance has replaced the term watchful 
waiting [126].
Still a number of open questions result:
1)  Who are suitable candidates for an active surveillance policy?
2) How can they be selected? 
3) How to monitor these men in order not to lose the window of cure?
4)   When should deferred treatment with curative intent take place?
Selection of patients
Because AS offers patients deferred treatment with curative intent, males with slowly 
progressive, small volume and well differentiated organ confined disease at diagno-
sis are the best candidates [127]. At present time a large portion of these males will 
have been (over)diagnosed with PCa due to screening. Chapter 3 gives an overview 
of the conservative policies in the literature including AS and discusses selection and 
monitoring criteria. In the following section follows a short introduction of the different 
parameters used.
Follow-up of patients
After the identification of minimal PCa deferred treatment only is a viable option if 
tumour dynamics can be monitored. PCa is by definition a progressive disease and 
progression can arise on three levels, biochemically, histologically and clinically.
Biochemical progression
With surgery the whole prostate gland and the vesiculae seminales are removed. There-
fore no production of PSA should be present and PSA should not be detectable in serum. 
When PSA levels become detectable after surgery there is either recurrence of disease, 
metastasized disease or the resection was incomplete. The most widely used definition 
of biochemical progression of PCa after radical surgery is a confirmed measurable PSA 
level [12, 13]. The definition used for biochemical progression of disease in the thesis are: 
three consecutive rising PSA levels after radiotherapy according to the recommenda-
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tions of the American Society for Therapeutic Radiology and Oncology (ASTRO) [13]. No 
definitions are currently available for patients treated with an AS regimen, however PSA 
kinetics over time might provide useful information. Based on the assumption that PSA 
is correlated with PCa volume [128], and that prostate cancer cells continue to produce 
PSA which is shed into the bloodstream due to disruption of the basal membrane [19, 
20], sequential PSA measurements over time could reflect tumour growth. It has been 
stated that one Ml of benign hyperplastic prostatic epithelium produces 0.3 ng PSA 
while the same amount of PCa tissue generates 3.5 ng PSA [11]. 
PSA velocity (PSAV) is the absolute rise of the serum PSA level in ng/mL per year [129]. 
For example a PSA level of 4 ng/mL at diagnosis rising to 4.2 and 4.3 ng/mL after respec-
tively three and six months gives an absolute rise of 0.3 ng/mL in six months and a PSAV 
of 0.6 ng/mL/yr.
PSA doubling time (PSADT) is the time in years needed to double the original PSA level 
[128]. The use of PSADT is based on the assumption that PSA levels rise linearly in males 
without PCa, whereas these levels will rise exponentially, in line with cancerous growth, 
in PCa patients. To calculate PSADT the 2log(PSA) levels (2log(PSA) = 10log(PSA)/log(2)) 
are plotted against time since diagnosis. The PSADT is the reciprocal coefficient of the 
linear regression line through these points. The 2log(PSA) is used to minimize differ-
ences in PSA levels at diagnosis. Ideally at least three PSA values taken at a minimal three 
month interval are used. A PSADT of 10 years or greater is assumed to reflect indolent 
PCa whereas as PSADT of two years or shorter probably represents aggressive fast grow-
ing PCa.
Figure 8 shows an example of a patient with a rising PSA from 2 ng/mL to 4, 8 and 16 ng/
mL in three years time. This corresponds to a PSAV of (16-2)/3 = 4.6 ng/mL/year. Likewise 
the PSADT is 1 as the coefficient of the line through the 2log(PSA) values is one. If the 
PSA would rise in from 2 to 16 ng/mL in one year the PSADT would ¼ yr or 3 months.
Histological progression
The only way to monitor histological progression is to perform repeat prostatic biopsies 
or a (radical) prostatectomy. Histological progression can occur on two levels, namely, 
the tumour load increases due to growth, i.e. more biopsy tissue with PCa or, the tumour 
dedifferentiates into a higher Gleason pattern, i.e. from 3 to pattern 4 or 5.
Pitfalls in interpreting biopsy data can occur on two levels [130]. Firstly, prostatic bi-
opsies are a sample of the whole prostate and thus sample errors can occur. As PCa is 
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a multifocal disease it can happen that the most predominant Gleason pattern is not 
represented in the biopsied cores, or that the amount of PCa is too limited to clearly 
discriminate the two most prevalent patterns, especially in larger prostates. This is called 
reverse sampling. In a sample error an entire focus of PCa is missed. The risk of error 
increases with the size of the prostate as the chance of missing a focus rises. Currently 
the number of biopsies that should be taken is subject to discussion. Multiple groups 
state that PCa detection rates increase with the number of biopsies taken, ranging from 
6 to up to 32 cores per session [131-133]. A recent review however, showed that with 12 
cores harvested there is balance in the cancer detection rate and adverse events [132]. 
On the other hand one prospective randomized study showed no statistical significant 
difference in cancer detection rates comparing a lateral guided sextant biopsy and a 
regimen where twelve lateral biopsies were taken [134]. In the ERSPC a lateral directed 
sextant biopsy procedure is used, added with an extra lesion directed biopsy when a 
hypoechoic lesion is visible in both the sagital and the longitudinal plane at TRUS. The 
cancer detection rate with the lateral sextant biopsy is 85% [135]. In the first round of the 
ERSPC, section Rotterdam, 436 (23.7%) men having a biopsy, had a hypoechogenic lesion 
and an additional biopsy. In these men, 230 cancers were detected (52.8%), but only in 
3.5% (eight of 230) it was solely this lesion directed core that showed malignancy [136]. 
Though the prostate cancer detection rate from the biopsy cores taken from the suspect 
lesion in the ERSPC section Rotterdam are low [136], an analysis of men undergoing a 
biopsy procedure at the second screen visit and a benign biopsy session 4 years before 
revealed no indication to change the biopsy protocol in the Rotterdam section [137]. 
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8
16
2 3
4
2
4
10
5
10
15
0 1 2 3
Time in years
PSA in 
ng/mL PSA
2log(PSA)
2log(PSA) = 10log(PSA) / 10log(2)
PSADT = 1/ linear regression line through 2log(PSA) values
PSAV   = 16-2 / 3  = 4.6 ng/ml per year
PSADT = 1 / 1 = 1 year
Figure 8. PSA calculations.
34 Chapter 2
Secondly, interpretations of pathologist can differ which is called inter-observer vari-
ability [138]. This variability is limited in the ERSPC, section Rotterdam, as all cancers are 
reviewed by one uro-pathologist (ThvdK) and according to a manual with guidelines on 
assigning Gleason Scores to prostatic biopsies [79]. 
In a clinical setting, Gleason grade progression in 241 patients with stage T1C PCa at 
diagnosis was uncommon [139]. All patients received annual repeat biopsies and grade 
progression occurred in 18.7 %. In 24 out of 45 males (53.3%) grade progression could 
be explained due to a sample error as degrading occurred within two years of diagnosis.
Clinical progression
Clinical progression can be local or caused by metastatic lesions. Progression of local 
clinical stage can be evaluated by a physical exam or, the DRE. For example, a previously 
impalpable disease transforms into a palpable lesion. This lesion, however, might also be 
the result of a previously performed biopsy procedure. 
If the PCa in its continuous expansion impairs voiding, by compressing or growing into 
the prostatic part of the urethra, some patients might need a transurethral resection of 
the prostate (TURP). Likewise it can grow into the urinary bladder, the pelvic floor, the 
external anal sphincter and less frequently into the rectum all of which can cause local 
symptoms.
Untreated aggressive prostate cancer will metastasize, firstly to the regional lymph 
nodes and from the non regional lymph nodes to preferably the bone, though visceral 
metastasis can occaisonally occur. Pain at preferential sites as the spinal column, the 
pelvis or ribs can be caused by an osteoblastic metastatic PCa lesion and can be visual-
ized with radiographic studies as CT-scan, nucleotide bone scan or X-ray studies.
suMMaRy
Active surveillance (AS) entails an active observation policy for men with localized pros-
tate cancer. The concept of AS is to avoid unnecessary treatment, with its inherent side-
effects and costs, while preserving the window of cure with active monitoring. Patients 
with screen detected PCa seem to be the most apt candidates due to the generated 
lead- and lenght-time associated with PCa screening. PSA kinetics as PSA velocity and 
PSA doubling time might be useful in monitoring patients on an AS policy. 
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IntRoDuCtIon
Prostate cancer used to be diagnosed in men aged ≈ 70 years; with the advent of PSA-
based early diagnostic regimens the lead-time (the period between screen detection 
and presumed clinical diagnosis) is increased and the age at diagnosis declines to ≈ 60 
years. Because men are relatively elderly at the time of diagnosis there is an obvious 
chance of intercurrent death, which was ≈ 2:1 in the past. Table 1 shows the incidence 
and mortality estimates, and the calculated ratio of the age-standardized rates in 
Western Europe, North America and worldwide [140]. In all geographical areas referred 
to, the ratio between incidence and mortality has increased over time. However, this 
change is much more drastic in North America, where screening for prostate cancer is 
highly prevalent. Here, based on statistics for 2000, one in almost six men diagnosed 
with prostate cancer was likely to die from the disease. 
How do these epidemiological data translate to the clinical situation? Can those patients 
who are unlikely to die from their disease be identified with reasonable certainty? Is 
it possible to avoid unnecessary treatment safely and how can that be achieved? The 
present review attempts to give answers to these questions. 
natuRaL hIstoRy anD a ReVIew oF ReCent Data
Almost all available data relating to the natural history of prostate cancer are based 
on clinically detected cases. Natural history data on screen detected cases of prostate 
cancer are at present unavailable but will be created as a result of the large ongoing 
screening studies worldwide. A more comprehensive review is given by Klotz et al. [125]. 
Diagnosis in the cited series was usually by biopsy and in some cases by TURP. As a result 
of this, focal and incidental prostate cancer derived from the transition zone of the 
prostate is included in an unknown proportion. Because of the resulting uncertainties 
in assigning clinical stage, most studies have given preference to the use of histologi-
table 1: Incidence and mortality estimates of prostate cancer in 2000
Adapted from [140].
Region Cases ASR* Deaths ASR* Ratio ASR
(N) (N)
Europe, West 84,856 54.9 30,777 19.3 2.85
North America 211,950 102.2 39,919 17.8 5.74
World 542,990 21.2 204,313 7.9 2.68
Legend
ASR, age standardized range.
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cal and cytological grade as the most important prognostic variable for stratification. 
Table 2 summarizes some of the results [75, 104, 106]. Data on overall survival are not 
age-corrected and therefore reflect to a large part the intercurrent mortality. Data on 
cancer-specific survival and mortality may be flawed by the uncertainties of the clinical 
determination of death from prostate cancer. However, the data are informative. There is 
a steep decline in the 5-, 10- and 15- year cancer-specific survival with increasing grade 
and, in [75], a steep increase in cancer-specific mortality with increasing Gleason scores. 
It is important to realise that most cases diagnosed with present diagnostic techniques 
fall into the moderately differentiated group (grade 2, Gleason 6). Cancer-specific 10-15-
year mortality of moderately differentiated cases in the data cited in table 2 is 18-30%. 
Obviously, the favourable group of prostate cancer which may not require immediate 
treatment must primarily be found within the groups of men diagnosed with grade 1 
and 2 or Gleason 4-6 cancers. However, biopsy grade alone does not discriminate suffi-
ciently. In using biopsy-based grading the lack of correlation between biopsy grade and 
the true histological grade determined on radical prostatectomy (RP) specimens must 
be considered. Narain et al. [141] found that a biopsy Gleason score of < 7 identified the 
same grading only in 54.8% of cases; 40.9% and 4,3% were found to have Gleason 7 or 
Gleason >7 tumours in their RP specimens. Kaplan Meier curves constructed accord-
ing to Gleason grade < 7 in biopsy and RP specimens showed a small but statistically 
significantly difference in disease free survival against the biopsy grade. Despite of these 
limitations the cited natural history data show that there are subgroups of patients who 
are not at risk of dying from prostate cancer even within 15 years. The identification 
of cancers which can be treated by watchful waiting (WW) with acceptable safety, the 
pattern and duration of follow-up, and the trigger points for treatment will be crucial 
elements for developing policies aiming at delaying or completely avoiding aggressive 
treatment. 
a ‘ wInDow FoR CuRe’ 
With the application of early detection measures such as PSA-driven screening for 
prostate cancer the diagnosis is advanced in time, i.e. the lead-time is increased. The 
lead-time is influenced by multiple factors, e.g. the sensitivity of screening tests, the 
speed of tumour development and age. The ongoing randomized screening studies 
worldwide lend themselves to the calculation of lead-time which, in this context can 
be defined as the elapsed period of time after which the yield of both the number and 
variety of prostate cancers in the subsequent round of screening is equal to that in the 
first round of screening. Auvinen et al. [94] calculated a mean lead-time of 5-7 years, 
which corresponds to a preclinical detectable phase of 10-14 years assuming that the 
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mean lead-time represents its midpoint. Draisma et al. [4] applied a micro-simulation 
model based on individual case histories of screen detected cases to the calculate lead-
time and over-diagnosis. They found that the lead-time is strongly dependent on age 
but amounted to 12.3 years in a screening program of men aged 55-67 years. It must 
be assumed that the lead-time is shorter for aggressive and longer for indolent cancers. 
This information will become available from the ongoing randomised screening studies 
in Europe and in the USA. 
The increment in lead-time by applying early-detection measures is associated with a 
significant stage shift towards more locally confined and less aggressive cancers [142]. 
table 2: Survival and cancer specific survival of conservatively managed prostate cancer by grade (from 
selected references)
Survival, overall/cause specific, % 
(range) at
Reference N 5 years 10 years 15 years
[104]* Grade
1 9,804 -/-
54 (52-56)/ 93 
(91-94) -/-
2 6,198 -/-
38 (36-41)/ 77 
(74-80) -/-
3
2,236 45 (41-50)/ 69 (56-78)**/ 63 
(44-77)***
17 (14-20)/ 45 
(40-51)
-/-
[75] Gleason score
2-4 138 -/- -/- -/4-7****
5 118 -/- -/- -/6-11
6 294 -/- -/- -/18-30
7 137 -/- -/- -/42-70
8-10 80 -/- -/- -/60-87
[106] Grade
1 492 -/98 (96-99) -/87 (81-91) -/-
2 265 -/97 (93-98) -/87 (80-92) -/-
3 63 -/67 (51-79) -/34 (19-50) -/-
Legend
*All data according to intention to treat; 
**AJCC stage 1; 
***AJCC stage 2;
 ****% of men dying within 15 years from prostate cancer according to the age range.
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The long lead-time, stage reduction and natural history data cited above indicate that at 
least for properly selected cases there should be a long ‘window’ of time during which 
observation is appropriate without losing the opportunity for cure. This is also supported 
by available evidence from nomograms, prognostic tables and by the only available ran-
domized study of observational treatment against RP. Holmberg et al. [108] randomized 
695 patients with clinically diagnosed, non screen detected prostate cancer (TNM stage 
T1b, T1c and T2) including 35 cases with Gleason 8-10, between RP and observation. 
With observation alone (not followed by potentially curative measures) at a median 
follow-up of 6.2 years, 8.9% (31 of 348) men died from prostate cancer. Considering this 
same obviously relatively short observation period, 17 men needed to be treated to save 
one cancer death. The Partin tables [76] relate the occurrence of extraprostatic exten-
sion diagnosed on the RP specimen to clinical stage, PSA and biopsy Gleason score. In 
this context the event of extraprostatic extension is likely to limit or exclude curability. 
Clinical T2a disease, a PSA value of 2.5-4.0 ng/mL and a Gleason score of 5-6 is associated 
with extracapsular extension in 27% (range 23-31%) of cases. A rise of PSA to 4.1-6.0 and 
6.1-10.0 ng/mL increases this probability by 5% for each step. These data illustrate the 
risk taken if, in a WW policy, a rise of PSA to 6.0 or 10.0 ng/mL is accepted. If, as will be 
shown later, doublings of PSA may occur within <1 year or > 10 years, information used 
in prognostic tables and nomograms is likely to be helpful in designing WW strategies. 
DeFInItIons
WW should be clearly differentiated from ‘observational’ treatment as used in the natural 
history studies and the control arm of the Scandinavian Prostate Cancer Group study 4 
[108]. Treatment by observation does not aim at the eventual cure of a given patient but 
at the determining the proper timing for instituting of endocrine (palliative) treatment. 
Such policies were previously based on doubts about the effectiveness of curative forms 
of management of localized disease e.g. RP and radiotherapy. Observational treatment 
may be indicated in men with prostate cancer whose life-expectancy is limited due by 
age or concomitant disease. This option entails that these two factors must considered 
in each treatment decision. Estimates of comorbidity are possible according to well es-
tablished scoring systems. WW entails the observation of selected patients to determine 
which cancers should be treated by potentially curative measures and at when. The 
expected result is that some men, because they do not have aggressive disease, may 
not require any treatment because their cancer does not progress to clinical disease 
during their lifetime. The steps to be taken in WW are schematically indicated in Fig. 1. A 
logical consequence of the definitions given above is that patients who are not eligible 
for potentially curative management because of age or poor general health should not 
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be managed according to WW but according to observational regimens. The latter issue 
is beyond the scope of this review. 
CRIteRIa FoR seLeCtIon 
Criteria for selecting of patients for WW have not been established. Ideally, patients 
should be selected who either will not show progression during their lifetime or, if they 
show progression, will still be eligible for curative management with a high chance of 
success. The necessity for further research in this area and for determining prospectively 
evaluated appropriate criteria comes from the need to avoid unnecessary treatment, 
with its inherent side-effects and costs.
PRosPeCtIVe anD RetRosPeCtIVe stuDIes
Several reports on prospective and retrospective studies are available; the selection 
criteria used in six recent papers [122-124, 143-145] are summarized in Table 3. A broad 
spectrum of available prognostic factors were included, but their role is often overruled 
Figure 1. Flow diagram for WW in patients with prostate cancer
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by considerations of comorbidity and age. In this respect only one study [145] and pos-
sibly another [122] represent prospective evaluations of WW. Post et al. [146] describe 
a 3-year overall survival of 89% in patients with prostate cancer with no concomitant 
disease, using an adapted Charlson classification, which deteriorated statistically signifi-
cantly to 73% in patients with two or more concomittant diseases. The authors calculated 
multivariate hazard ratios (95% CI) for dying of 2.0 (1.0-4.3) and 7.2 (3.1-16.6) in patients 
aged 60 with one and ≥ 2 concomitant diseases, respectively. In this study, comorbidity 
was the most significant prognostic factor, especially in patients aged < 70 years in the 
first 3 years after diagnosis, followed by histological grade. Fowler et al. [147] describe a 
5.7 times greater age-adjusted risk of comorbid death in men with severe comorbidities 
compared to those with none in patients with T1b and T2NXM0 prostate cancer treated 
with surgery or radiation therapy. Barry et al. [105] reported that the Charlson score 
in their retrospective analysis of patients with clinical M0 disease was an independent 
predictor of worse outcome in terms of a shorter overall survival, whether patients were 
treated with RP, radiotherapy or expectant management. In no treatment method did 
the Charlson score remain an independent predictor of cancer-specific death. However, 
evaluating prognostic factors at entry relative to disease progression contributes impor-
tantly to a better understanding and to better future choice of entry criteria. McLaren 
et al. [143] found that only initial PSA and PSA doubling time (PSADT) obtained during 
the follow-up correlated significantly with clinical progression and other endpoints. In 
the study by Choo et al. [122] none of the pretreatment variables correlated significantly 
with PSADT, which was a predictor of progression in that series. Stephenson et al. [123] 
found a significant correlation between ‘clinically significant’ histology, T-stage and 
findings at repeat biopsy, but not with Gleason score and PSADT, which also in that 
study was the most important prognosticator during the follow-up. Zietman et al. [144] 
found that age was the most important determinant of remaining free from therapeutic 
intervention. Only the work by Carter et al. [145] addressed systematically the relation 
between disease progression and prognostic factors at entry. Only PSA density (PSAD) 
and free/total PSA (f/tPSA) had a significant correlation. Age, PSA at diagnosis, prostatic 
volume and PSA velocity did not correlate. However, the overlap of data relating to PSAD 
and f/tPSA also limited, in the view of the authors, the usefulness of these two variables 
in selecting patients.
PRoGnostIC VaLue oF bIoPsy FInDInGs
In line with the development of PSA derivatives, biopsy variables like the Gleason score, 
the number of positive cores, total length of cancer invasion in one core or the maxi-
mum percentage of core length invaded by cancer, are described as having predictive 
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value in estimating biochemical recurrence of disease [148-150]. A major pitfall in using 
biopsy-derived variables, as adressed elsewere in this review, is the representativeness 
of tumour characteristics, especially the Gleason score, in biopsy cores compared with 
the reference standard, the RP specimen [74, 141, 150-152]. Some groups [153] find a 
better correlation when extending the number of biopsies while others cannot detect 
this improved correlation [154, 155]. On the other hand Bastacky et al. [156] stated that 
perineural invasion on the biopsy in patients with clinical stage B disease correlated with 
extracapsular disease in 93% of RP specimens. Bonin et al. [157] showed that perineural 
invasion in a biopsy core was associated with biochemical recurrence of disease after 
three-dimensional conformational radiation therapy. Biopsy cores with higher tumour 
yield, e.g. tumour present in more than half of one core, more than three positive cores, 
or > 3 mm length of tumour invasion in one core, predicted biochemical progression in 
up to 90% of patients within 18 months after RP [74, 148, 158]. These patients should 
therefore be excluded from entering a WW policy. 
Peller et al. [159] identified 92% of organ-confined disease using RP specimens when 
one biopsy was positive. Others [148, 160] found that 80 % and, respectively, > 90% of 
patients had no biochemical progression 2 years after RP if the total length of invasion 
of cancer was <15%, or respectively, <20% of the total length of biopsy cores minus peri-
table 3 Selection variables for WW
Reference Variables, median range Status of study N 
men
Median (range) 
follow-up
[143] Age 75 (49-85)
T1a-T3c, PSA 5.8 (0.2-21) ng/mL
MD Anderson grade 1-3, Gleason scores 2-7 
Comorbidity, patient request
Prospective 113 14 (0-58) months
[122] Age 70 (49-84), stages T1b-T2b
PSA 6.5 (0.3-14.6) ng/mL
Gleason scores 3-7
Prospective 206 29 months
[124] Age 75 (44-87), stage T1-T2*
PSA 7.4 ng/mL (mean 12.3)
Gleason scores 2-10
Prospective (CaPSURE 
database)
329 -
[123] Age 69 (51-86), T1a-T3
Mean PSA 7.4 (0.9-25.2) ng/mL
Gleason scores 2-10
Clinically significant/insignificant 68/20%
Mean PSA density 0.19 (0.02-0.55)
Prospective 104 33 months
[144] Age 71, T1a-T2c, PSA < 20 ng/mL (median 6.6)
Gleason scores ≤ 8, comorbidity
Retrospective 199 3.4 years
[145] Age 65 (52-72), T1c ‘small volume’
Gleason 4-6, ≤ 2 biopsies with cancer or <half 
cancer in any core
Prospective 81 > 1 year (12-58 
months)
Legend
* >95% T1 or T2
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prostatic tissue. Epstein et al. [150] stated that prostate cancer was insignificant if the 
maximal length in any core was < 3 mm, Gleason score <7 and a PSAD < 0.15, or a PSAD 
< 0.1 with a Gleason < 7 and if fewer than three cores had cancer invasion in a maximum 
of half of any core. The algorithms of others also include PSA or PSA-derived variables, a 
Gleason score < 7 and minimal biopsy findings, thereby clearly illustrating the correla-
tion between greater tumor load and recurrence of disease [73, 161-163]. Eligible for a 
WW policy on the basis of biopsy findings could be patients with; (i) a Gleason score <7 
combined with a PSAD of < 0.1 ng/mL/g and (ii) only one biopsy core positive for cancer, 
a length of < 3 mm, respectively, 30% of cancer in that core or <20% cancer invasion of 
the total biopsy length. When the results from ongoing randomized screening studies 
are available these criteria will probably need adjusting.  
PoLICy PRoPosaL I: PatIent seLeCtIon
Selecting patients for WW should be differentiated from selecting them for delayed pal-
liative treatment (observation). This entails that a high ASA score or Charlson score, or an 
age-related condition that precludes surgery or radiotherapy should exclude patients 
from WW regimens. As indicated above, WW aims to identify those men who do not 
progress or who, if progression occurs, can be identified in a potentially curable state. 
Data from available studies, which allow the determination of patient selection for WW, 
are scarce. A proposal is given in Table 4. Patients who are too old or too sick for treat-
ment do not qualify for WW policies but for observational treatment. In most centres 
patients up to 75 years old would be eligible for RP if they have > 10 years of life ex-
pectancy; other centres would choose radiotherapy if the tumour is aggressive in older 
patients. Good general health with an ASA score ≤ 3 and a Charlson score ≤ 2 at the time 
of diagnosis can be considered a prerequisite for the future consideration of surgical 
management. The eligibility for radiotherapy may include men in poorer health. Carter 
et al. [145] chose the T1c classification as entry criterion for their study, but Choo et al. 
[164] and others also suggest that also palpable, locally confined disease, specifically 
T2a included cases with very low rates of progression. As for the PSA threshold, Carter et 
al. [165] showed that when the initial PSA level was greater than 5.0 ng/mL 30% of 317 
cancers were incurable (pT3). In the experience of the European Randomized Study of 
Screening for Prostate Cancer (ERSPC), section Rotterdam, a PSA of 8 to 10 ng/mL was 
associated with 25% of T3-4 and 25% of pT3-pT4 cases. PSA density and f/tPSA might be 
of additional value in using PSA values in this context. Considering the data by Albertsen 
et al. [75] and the choice made by Carter et al. [145] a Gleason score < 7 seems a reason-
able threshold. These considerations can be overruled by patient request if quality-of-
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life considerations, mainly the risk of loss of potency, become a dominant factor in the 
clinical situation. A threshold relating to the amount of cancer found in biopsies was not 
explored in any of the studies. Suggestions could be derived from the information given 
in the section on the prognostic value of biopsy findings.
FoLLow-uP oF ww
Ideally, the procedures used in selection and follow-up of patients assigned to WW regi-
mens should be correlated with recognised outcome parameters, e.g. overall and cancer 
specific survival. Unfortunately such information is not currently available. In attempts 
table 4: Policy proposals for WW
I Selection 
Patients < 75 years, life expectancy > 10 years
Good general health (ASA score ≤2, Charlson score ≤1)
T1a, T1c or T2a 
PSA < 5-8 ng/mL (and/or PSAD < 0.1 and/or f/tPSA ≥ 19%?)
Gleason score ≤ 6, no Gleason pattern 4
Patient request (quality of life considerations), applicable to 
higher risk after proper information
≤ one core positive for cancer with < 30% cancer 
involvement 
II Follow-up recommendations
Timing   3-6 months, 3 monthly during year 1 and 2
Physical   DRE - exclude T-progression
Laboratory  PSA and PSADT, creatinine
Imaging   TRUS yearly and upon indication, possibly together with  
   biopsy (support for DRE, volume)
Biopsy   Every 12-18 months (grade progression?) 
   Option: biopsy after 3 months
III Trigger points for treatment
 1. Patient request
 2. Local T progression (DRE or TRUS)
 3. PSADT < 2 years 
 4. Grade progression on biopsy
 (≥ two Gleason scores, or Gleason pattern 4)
 5. Any combination of items 2-4
PSAD, PSA density; DRE, digital rectal exam PSADT, PSA doubling time; PSAV, PSA velocity; TRUS, 
transrectal ultrasound.
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to still evaluate selection and follow-up procedures authors have chosen to consider the 
relationship of entry criteria and, in some instances, PSA and clinical progression rates, 
with information obtained during follow-up. Trigger points for treatment are often the 
result of arbitrary choices. Their effect on surrogate outcome variables will be reviewed 
later.
Table 5 gives a summary of follow-up regimens used in the watchful waiting studies 
chosen for review [122, 123, 143-145]. Most authors considered a follow-up interval of 
3-6 months adequate and safe. A 3-monthly interval, at least during the initial period 
of follow-up, offers the advantage of accumulating many PSA values which gives the 
opportunity to consider biological variation and to calculate the PSA doubling time 
(PSADT). All authors perform a rectal examination during the follow-up visits, the main 
purpose being to detect progression of the originally assigned T-category. PSADT is also 
used within all studies and was found to correlate with clinical progression [123, 143, 
144]. Several groups reported no correlation between PSADT and baseline variables 
[122, 123, 166]. A repeat biopsy, with the main goal being to detect grade progression, 
was taken either 6-monthly, yearly or 18-monthly, or on indication by four groups [122, 
123, 144, 145]; biopsy protocols vary from six to 12 cores. In two of the cited references 
there was a weak correlation with either PSAV or f/tPSA and progression and/or baseline 
characteristics [145, 166]. 
In summary, most authors feel that patients on WW should be followed at 3 to 6-monthly 
intervals, and 3-monthly during the first 1 to 2 years. All authors used PSA and rectal 
examination; serum creatinine and free PSA was recommended by some. Bone scans 
are carried out on clinical indication or if the PSA increases to > 15 ng/mL. It is well 
documented that for a serum PSA of 20-50 ng/mL the rate of positive bone scans is ≈ 8%; 
at > 50 ng/mL the rate is 16% [167]. Clinical progression is diagnosed with an increase of 
table 5 Follow-up regimens used in WW studies
Reference Regimen
[143] 3-6 monthly visits, PSA, PSADT, DRE, clinical progression increase in T-category
[122] 3-monthly for 2 years, then 6 monthly, prospective evaluation, PSADT, f/tPSA, prostatic acid 
phosphatase creatinine, TRUS (6-monthly), re-biopsy after 12-18 months, bone scan after 1 and 2 
years then every 2 years, with PSA >15 n/mL every year
[123] 3-6 monthly follow-up, PSA, DRE, bone scan ‘if indicated’ sextant biopsies yearly, PSADT
[144] 4-6 monthly follow-up, PSA, DRE, repeat biopsy upon indication, PSA increase
[145] 6-monthly follow-up, PSA, DRE, TRUS an biopsy yearly (≥ 12 cores), PSADT, PSAD, PSAV, f/tPSA
Legend
DRE, digital rectal exam; PSAD, PSA density; PSADT, PSA doubling time; PSAV, PSA velocity; TRUS, 
transrectal ultrasound.
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the T-category, a rise in serum creatinine caused by ureteric obstruction, an increase in 
Gleason score on re-biopsy, or if there are cancer-related specific complaints. 
This information is summarized in Table 4; obviously, follow-up regimens need to be 
viewed against the background of the available outcome data. These will be referred to 
in the discussion of trigger points for treatment. 
InDICatIons FoR tReatMent
Almost all aspects of the application of WW to locally confined prostate cancer are still 
investigational. Candidate prognostic indicators for triggering treatment decisions are 
usually arbitrary, often governed by uncertainties and the patient’s wishes resulting 
from the psychological stress of slowly rising PSA levels. While future research will also 
consider the prognostic factors available at the time of diagnosis, important informa-
tion can be gained during follow-up which is likely to identify those cases that tend to 
progress to a potentially incurable stage. The candidate criteria listed in table 4 are now 
assessed as potential indicators for treatment or continued observation for patients who 
have chosen WW. 
Psa ChanGe oVeR tIMe 
Many attempts have been made to correlate PSA change over time in various clinical 
situations to outcome parameters. Davidson et al. [168], in a multivariate analysis cor-
relating progression in lymph-node positive disease to outcome, reported that a 20% 
increase in PSA was the most sensitive and specific indicator of progression. Carter et al. 
[169] using data from the Baltimore longitudinal study of ageing defined PSA velocity 
as the increase of PSA per year, noted that a change in the very slow increase in PSA 
in patients with benign disease, of 0.04 ng/mL/year to a PSA velocity of 0.75 ng/mL/
year occurred 7.3 years prior to the diagnosis of clinical prostate cancer. This group also 
found that many observations over a period of ≥ 2 years were necessary to take account 
of the biological variation of serum PSA when calculating PSA slope and doubling times. 
In comparison, Ciatto et al. [170] found an average PSA velocity (two values) in healthy 
subjects of 0.07 ng/mL/year. Several groups have addressed the best way of determining 
of PSA rise and there seems to be growing consensus that PSA doubling time (PSADT) is 
the most suitable parameter. Choo et al. [164] used the following equations: 
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PSA (t) = PSA (0) eλt
ln PSA (t) - ln PSA (0) + λt
Td=ln 2/λ
where PSA (0) is the initial PSA, PSA (t) the PSA at time t after PSA (0), and λ is the slope; 
the rate constant does not correlate with baseline variables age, PSA, T category or 
Gleason score.
Schröder et al. [171] have proposed a fitting procedure in determining PSA slope; a 
similar procedure was described by Guess et al. [172]. Unfortunately, apart from visually 
estimating doubling time from grafts or groups of data, exact calculations are complex 
and currently difficult to use in the outpatient setting. 
All considerations of PSA change with time are based on the assumption that PSA levels 
are related to tumour mass. It is recognised that clinical progression, usually of hormone 
unresponsive prostate cancer under endocrine treatment, may occur with no rise in PSA 
level. This issue was recently reviewed and quantified by new data by Collette et al. [173]. 
Several authors have attempted to establish a relationship between serum PSA levels 
and the volume of prostate cancer. Stamey et al. [174] found a significant correlation 
(r = 0.7) between pretreatment PSA and prostate cancer volume. Schmid et al. [128] 
indicated from the same database that 1 mL of prostate cancer on average correlated 
with 3.6 ng/mL of serum PSA. However, more recent data [175] do not reproduce the 
original data. There was no relevant or significant correlation between prostate cancer 
volume and pretreatment PSA, and the original data could not be reproduced. This is 
in line with other reports [145, 164] that PSADT does not correlate with pretreatment 
prognostic factors. Despite of these uncertainties, increasing evidence is emerging that 
increase in the PSA with time, especially expressed as PSADT, is a valuable prognostic 
factor. Clinical progression in locally confined disease with no increase in PSA seems to 
be extremely rare. 
Psa ChanGe wIth tIMe anD PRoGRessIon unDeR watChFuL waItInG 
There are many reports of PSA as an indicator of progression and outcome after the 
potentially curative management of prostate cancer. Several authors have addressed 
the predictive value of the PSADT beforehand for progression after treatment. Hanks et 
al. [176] reported on 99 patients with T1-3 prostate cancer in whom the pretreatment 
PSADT was assessed. With a PSADT of < 1 year and > 1 year, 47% and 11% had PSA 
progression after 18 months. Goluboff et al. [177] assessed 150 patients in whom the 
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PSADT was calculated prior to radical prostatectomy. 56 patients had 3 or more PSA 
measurements before RP; 56 had three or more PSA measurements before treatment. 
With a follow-up time of 17.3 months PSADT did not correlate with PSA failure, the final 
PSA value or the Gleason score of the RP specimen. 
The PSADT during WW situation is extremely variable; Choo et al. [164] in 134 patients 
with a median (range) of 24 (1-52) months and a median of seven PSA measurements, 
reported that the PSADT varied < 2 years to > 50 years in 27 of them. Carter et al. [169] 
estimated a normal PSADT with no cancer amounting to 54 ± 30 years at a baseline age 
of 40 years. Three of the available and reviewed reports on WW related PSA change over 
time to clinical progression. Stephenson et al. [123] reported in their study of 104 cases 
that a PSADT < 10 years correlated with disease progression on rectal examination and 
repeat biopsy, and with the presence of «significant cancer’ at the initial evaluation; 48% 
of the men had a PSADT < 10 years. A PSADT < 4 years in 27% of the men correlated 
significantly with T progression established by rectal examination. McLaren et al. [143] in 
113 cases reported a strong correlation of PSADT with several different thresholds of the 
time and rate of clinical progression. Their data are reproduced in Fig. 2. A multivariate 
analysis included PSADT and pretreatment variables (tumour grade, Gleason grade, ini-
tial PSA, T-classification). Only the PSADT remained significant in a multivariate analysis 
for predicting progression. PSA progression was not assumed to be clinical progression 
in this study. Carter et al. [145] found that PSA density was significantly higher and f/
tPSA was significantly lower in men with disease progression, which occurred in 25 of 81 
men (31%). Progression was determined by digital rectal examination and annual repeat 
biopsies. Age, PSA, prostate volume and PSA velocity were not statistically significantly 
related; the PSADT was not reported.
Figure 2: The Kaplan-Meier curves for PSADT as a predictor of activity during WW for PSADTs of <1.5 years 
(gray line), 1.5– 3 years (black line), > 3 years (gray dotted line) and static or decreasing (dashed black line).
Adapted from [143].
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Available data indicate that PSADT is a powerful predictor of clinical progression in 
patients managed by WW. The clinical utility needs to be established prospectively in 
larger series of men. The possibility of clinical progression with no PSA progression 
as reported by Stephenson et al. [123] has to be taken into account. Carter et al. [145] 
reported the outcome of RP in their follow-up series. Of 81 men with minimal T1c 
disease 25 had unfavourable biopsy findings indicating disease progression. Thirteen 
underwent RP within a median (range) time to progression of 14 months (12-52). 12 of 
these had curable disease. 
DIGItaL ReCtaL exaMInatIon
There is consensus that progression of T-stage on a DRE must be considered clinical 
progression [122, 123, 143, 144]; this is specifically true if impalpable disease (T1c) 
progresses to a palpable lesion. Usually the impression on a DRE will be confirmed by 
biopsy. Stephenson et al. [123] reported a disappointing correlation between clinical 
progression on DRE, biopsy and PSADT. 
RePeat bIoPsy
Repeat biopsies are recommended by most investigators after periods of 3-18 months 
[122, 123, 145, 178]. It is well established that repeat biopsy may not show cancer at all 
[179], but if there is upgrading this may be a result of having missed the less differenti-
ated parts of a prostate cancer with several architectural patterns. At present, consider-
ing the available reports, the repeat biopsy can be selected as an integral part of the 
follow-up procedures in WW. Multivariate analysis of the progression variables available 
during follow-up must establish their relative and absolute value in the future, making 
use of larger and well defined series of patients. 
PatIent Request FoR tReatMent ChanGe
In all WW series a large proportion of patients choose treatment because of the uncer-
tainties about a slow but steady rise in PSA level; psychological stress is important in this 
context. This decreases the value of the time to and the rate of change in treatment as 
a potential endpoint. 
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Currently it is impossible to develop an evidence-based policy proposal for treatment 
indications. Recommendations are summarized in Proposal III in Table 4. The patient’s 
request must be honoured. A short PSADT of probably < 2 years should provoke a con-
sideration of treatment or further evaluation. A histological upgrade by two Gleason 
scores or more at repeat biopsy has been used in several of the WW studies. Other 
variables are listed in Table 4. 
ConCLusIons
WW and observational treatment should be differentiated. Despite of considerable 
uncertainties about the risks and potential benefits of WW and the procedures applied 
for case selection, follow-up and delayed treatment, WW is used with an increasing 
frequency. In this review we have assessed the existing information relating to case se-
lection, follow-up and treatment indications. The preliminary data on the natural history 
of screen detected and clinically detected cancers suggest a long ‘window of treatment 
opportunity’. Considering the few available data on final outcome (progression to incur-
able disease) this risk seems to be small with the selection and follow-up procedures 
recommended in the policy proposals in Table 4. 
Future research must concentrate on the evaluation of entry criteria and follow-up 
procedures to establish the appropriate trigger points for treatment. In this respect 
observation studies and watchful waiting studies need to be separated. The ongoing 
randomized studies of screening for prostate cancer offer a good opportunity to develop 
this field further because they allow prospective observations in screen detected cases. 

Part II: 
Selecting patients for active 
surveillance
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abstRaCt
Introduction: 
This report describes survival data of participants of the European Randomized Study 
of Screening for Prostate Cancer (ERSPC), section Rotterdam, diagnosed with prostate 
cancer (PCa) during the first round of screening, the prevalence screen. 
Patients and methods:
PCa characteristics from cases diagnosed during the first screening round from Decem-
ber 1993 to March 2000 are shown. During follow-up, data were collected by semiannual 
patient chart review for the first 5 yr and annually thereafter. The causes of death are 
scored according to the diagnosis of the treating physician and are not based on the 
review of the independent causes-of-death committee. Overall and disease-specific 
survival graphs are shown in Kaplan-Maier projections and compared with expected 
survival outcomes for males in the same age categories from the Dutch provinces of 
North Holland and Flevoland. Statistical evaluation was based on Cox regression analysis. 
Results: 
During the prevalence screening, 1014 patients were diagnosed with PCa. Median 
follow-up was 55 mo, 126 (12.4%) patients died, 20 (2.0%) of PCa. Overall 5-yr observed 
and expected disease-specific survival was 97.7% and 82%, respectively. In the multi-
variate analysis, a Gleason sum of 4+4 or higher (p = 0.025) was predictive of PCa death. 
Conclusions: 
The observed survival data are in line with the literature and the expected favourable 
outcome for a screened population. The proportion of men dying from PCa is still small, 
and a 10-yr follow-up period for the final evaluation of the ERSPC may be too short.
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IntRoDuCtIon
Prostate cancer (PCa), unlike most other malignant diseases, has a protracted natural 
course in the majority of cases. Treatment after an early diagnosis of PCa, facilitated by 
screening, could possibly improve disease-specific survival [180]. Currently two large 
prospective randomized trials are investigating the effect of PCa screening on disease 
specific mortality [181]. While a beneficial effect of screening has yet to be determined, 
a shift towards more favourable tumour characteristics at diagnosis has been reported 
[67, 182]. This report describes, for the first time, the overall and disease-specific survival 
rates of patients diagnosed with PCa during the first round of screening in the Euro-
pean Randomized Study of Screening for Prostate Cancer (ERSPC), section Rotterdam. 
The goal of this early study of outcome parameters of PCa patients identified at the 
first screen in the ERSPC, Rotterdam is to put survival rates into perspective with the 
literature and with regional mortality data. 
PatIents anD MethoDs
Patients diagnosed with PCa during screening in the prevalence screen of the ERSPC, 
section Rotterdam, were included. The first round started in December 1993 after four 
pilot studies; recruitment and randomization ended in December 1999. A detailed over-
view of the inclusion criteria and test procedures used was recently published elsewhere 
[88]. Fig. 1 shows the flowchart of the ERSPC, Rotterdam screening round 1. In short, 
21,210 males were randomized into the screen arm and 19,970 patients (94.2%) were 
actually screened. Clinical staging in the ERSPC is done according to the 1992 UICC TNM 
classification [81]. The Charlson score was used to estimate the comorbidity status at 
diagnosis [183]. During follow-up data, were collected from semi-annual patient chart 
review for the first five yr and annually thereafter. Charts were checked for medical his-
tory, physical examinations, dissemination studies, and prostate-specific antigen (PSA) 
tests. To compare outcomes, we divided cases into three widely used prognostic groups 
[184]. In the study of D’Amico et al. [184] clinical stage is solely based on digital rectal ex-
amination (DRE) findings. Metastatic disease was diagnosed in case of new or increased 
radiographic evidence of metastases during follow-up. 
Within the ERSPC all deceased PCa cases are reviewed by a national independent cause-
of-death committee using predefined flowcharts or by an international committee if 
no consensus is reached [185]. All cases are reviewed blinded for personal information 
and trial arm; therefore these data are not yet available. However, during patient chart 
review, a preliminary cause of death is scored according to the diagnosis of the treating 
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physician; these scores were used for the survival analysis. Expected overall mortality for 
every subsequent year was calculated by multiplying the Dutch age-specific mortality 
quotient in the period 1996 to 2000 with the number of men in the cohort. For the first 
year the mortality quotient of the age group of 66.5 yr was used (median age study 
cohort: 66.7); for the second year the mortality quotient in the age group of 67.5-year-
old men was taken, and so forth. The number of deceased males was subtracted from 
Fig. 1 Flowchart for the European Randomized Study of Screening for Prostate Cancer (ERSPC), section 
Rotterdam. Adapted from [88].
Fig. 1 Flowchart for the European Randomized Study of Screening for Prostate Cancer 
(ERSPC), section Rotterdam. Adapted from [88]. 
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level < 4 ng/ml. 
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the cohort before the next calculation. The expected disease specific mortality is the 
reported disease-specific survival of Dutch males diagnosed with PCa at 60 to 74 yr of 
age during the periods 1988-1991, 1992-1995, 1996–1998, and 1999-2001, in the Dutch 
provinces of North Holland and Flevoland [186]. The absolute numbers of patients 
diagnosed in these periods were 1,787, 1,525, and 1,690 respectively. The reason for 
using these data was that disease-specific survival was provided per year. A regression 
trendline for each category was plotted for illustrative purposes. 
Statistics
Distribution of parameters between the different treatment modalities is calculated 
with the use of the Pearson-Chi square test for categorical variables and the Kruskal-
Wallis test for all continuous variables. Kaplan-Meier analysis was used for overall and 
disease-specific survival. The Cox proportional hazards regression model was used to 
calculate hazard ratios (HRs) and 95% confidence intervals for prognostic factors. A HR 
can vary from zero to any positive value and gives the relative risk for one unit increase 
in the predictor at any time. For example, the HR of age at diagnosis as a continuous 
variable is 1.07, which means that a patient aged 67 yr at diagnosis has 1.07 times the 
risk of dying of any cause compared with a 66-year old patient at any time of follow-up. 
After 5-mo follow-up, this hazard has exponentially increased to [100%*(1.07 5)]-100% 
= 40.3% for the 67-year-old man. The HR in the categorical variables reflects the relative 
hazard, compared to the reference group. The largest groups, which in this study also 
had the most favourable PCa characteristics, were made the standard. All analyses were 
performed with the commercially available Statistical Package for the Social Science 
software, version 12.0 (SPSS Inc, Chicago, IL, USA). 
ResuLts
During the prevalence screening, 1,014 males were diagnosed with PCa. One patient 
retracted his written consent, and, in one patient, treatment modality is not yet known. 
Median follow-up was 55.1 mo. Table 1 shows the baseline data of 1,013 cases. All pa-
tient characteristics shown in table 1 were distilled into three prognostic groups and 
were statistically significantly different (p < 0.001) between the treatment groups (Table 
2). The majority of cases (87.7%) directly received treatment with curative intent (Fig. 
1). During follow-up a total of 126 (12.6%) patients died, including 20 from PCa. The 
5-yr observed cumulative survival in the screen cohort was 88.3% while the expected 
5-yr overall survival was 85.7%. Initially, the observed overall survival was higher than 
expected overall survival, but with extended follow-up both survival projections were 
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similar (Fig. 2A). The observed 5-yr disease-specific survival in the ERSPC, section Rot-
terdam, was 97.6%, which was higher than the 82% in the cohort of men diagnosed 
between 1996 and 1998, or the 76% of men diagnosed between 1992 and 1995 in the 
Dutch provinces of North Holland and Flevoland (Fig. 2B). 
Table 3 shows the number of men treated by radical prostatectomy (RP), radiotherapy 
(RT), watchful waiting (WW), and endocrine treatment (ET) stratified into three prog-
nostic groups. The numbers of PCa and intercurrent deaths are provided. Because of 
limited events, only the PCa-specific survival for the high-risk prognostic group could 
be calculated (Fig. 3).
table 1 Baseline characteristics of the cases detected in the prevalence screen of the ERSPC, section 
Rotterdam
  Total (% or range) p value #
Patient n (%) 1013 (100)
Age at diagnosis (yr, median range) 66.7 (55 - 75) <0.001
Follow-up (mo, median range) 55.1 (0 -114) <0.001
PSA (ng/mL, median range) 5.7 (0.3 - 315) <0.001
Clinical PSA group ≤ 4^ 262 (25.8) <0.001
4-10 518 (51.2)
>10 233 (23.0)
T stage [194] T1C^ 357 (35.2) <0.001
T2 468 (46.2)
T3 177 (17.5)
T4 11 (1.1)
Biopsy Gleason sum ≤ 3+3^ 635 (62.6) <0.001
7* 284 (28.1)
≥ 4+4 82 (8.1)
unknown 12 (1.2)
Charlson score 0^ 532 (52.5) <0.001
1 314 (31.0)
≥2 167 (16.5)
Prognostic groups [184] Favourable^ 461 (45.4) <0.001
Intermediate 291 (28.8)
High risk 261 (25.8)
Legend
ERSPC: European Randomized Study of Screening for Prostate Cancer; PSA: prostate specific antigen.
* Including 18 patients with a Gleason score of 4+3.
# p values for continuous variables as age, PSA and follow-up are calculated with the Kruskal-Wallis test 
for the remaining categorical variables the Pearson chi-square test was used.
^ Reference category in Cox-regression analysis.
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All baseline characteristics shown in Table 1 were tested in univariate and multivariate 
analysis for their predictive value of overall mortality. The results are summarized in Table 
4. Statistically significant predictors at diagnosis for overall death in the univariate analy-
sis were age (p< 0.001), a Charlson score of 1 (p=0.003) or 2 (p<0.001), a clinical stage 
T3 disease (p=0.003), a biopsy Gleason sum of 4+4 (p<0.001), or patients in the high-risk 
prognostic group (p<0.001). The hazard ratio of 3.2 for patients with a Charlson score 
of two or higher, for example, means that, at any point during follow-up, these patients 
have a 3.2-fold increased risk of dying, compared with patients with a Charlson score 
of zero, who functioned as the reference group. The other reference groups are listed 
in Table 1. In the multivariate analysis age (p=0.013), a Charlson score of 1 (p=0.029) 
or 2 (p<0.001), clinical stage T3 disease (p=0.026) and a biopsy Gleason score of 4+4 or 
higher (p=0.036) remained statistically significant predictors for overall mortality. 
PCa death occurred in 4 patients after RP (2 of perioperative complications), in 10 after 
RT and in 6 after ET. Of the 20 PCa deaths, 17 cases had high-risk PCa characteristics. 
The patient with favourable PCa characteristics died of perioperative complications. Of 
the two patients with intermediate characteristics dying of PCa, one appeared to have 
tumour growing into the bladder at pathologic examination. The other patient, who was 
treated with RT, had organ-confined PCa at DRE, but within a year after therapy capsular 
penetration was seen on transrectal ultrasound evaluation as well as a fast rising PSA 
level for which ET was started. No patient initially managed with a WW policy died of 
PCa, although during current follow-up 15 patients received deferred treatment with 
curative intent after an initial WW policy (RP= 3 and RT= 12). Moreover of the remain-
ing 85 males, 6 patients currently have ET, 3 had metastatic disease at diagnosis that 
became symptomatic, 2 had local progression and 1 had a rising PSA. 
Testing the baseline PCa characteristics in the univariate analysis for PCa-specific mortal-
ity, PSA as a continuous variable (p<0.001), patients with a PSA level > 10 (p=0.009), a 
biopsy Gleason score of 4+3 (p=0.003), a clinical stage T3 (p=0.025), or T4 (p<0.001), and 
patients with high-risk PCa characteristics (p=0.001) were at increased risk of dying of 
PCa. The corresponding HRs (95 confidence intervals [CIs]) are 1.01 (1.01-1.02), 7.3 (1.7-
32.6), 22 (2.9-169), 13.5 (1.4-130), 30 (8.5-106) and 30.4 (4-229) for patients with high-risk 
PCa characteristics. In the multivariate analysis only males with a Gleason score of 4+4 
(p=0.025) remained at a statistically significantly increased risk of 7.0 (1.3-37.7) of dying 
of PCa compared with patients with a biopsy Gleason sum of 3+3. 
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table 2 - Distribution of comorbidity and prostate cancer characteristics between treatment groups
 RP 
n=399
% RT 
n=490
% WW 
=100(%)
ET n=23 % Total n=1012  %
Charlson Score = 0 257 (64.4) 218 (44.5) 44 (44) 12 (52.2) 531 (52.5)
1 96 (24.1) 176 (35.9) 36 (36) 6 (26.1) 314 (31.0)
>1 46 (11.5) 96 (19.6) 20 (20) 5 (21.7) 167 (16.5)
“Favourable” PCa 
[184]
223 (55.9) 160 (32.7) 75 (75) 2 (8.7) 460 (45.4)
“Intermediate” PCa 119 (29.8) 156 (31.8) 15 (15) 1 (4.3) 291 (28.8)
“High risk” PCa 57 (14.3) 174 (35.5) 10 (10) 20 (87.0) 261 (25.8)
Legend
Favourable PCa: T1C or T2A and PSA ≤ 10 ng/mL and Gleason score ≤ 3+3
Intermediate PCa: T2B or PSA < 20 ng/mL or a Gleason score of 7
High risk PCa: ≥T2C, PSA > 20 ng/mL or a Gleason score ≥ 8
PCa: prostate cancer; PSA: prostate-specific antigen; RP: radical prostatectomy; RT: radiotherapy; WW: 
watchful waiting; ET: endocrine treatment.
Fig.2
Fig. 2a Observed versus expected overall survival. 
Fig.2 (A) Observed versus expected over ll survival. (B) Comparision of disease-specific 
survival of the Eur pean Rando ized Study of Screening for Prostate Cancer (ERSPC) 
prevalance screen cohort with the observed PCa- specific mortality of Dutch males diagnosed 
at the age of 60-74 yr during four different time periods [186]. 
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Fig. 2b Comparision of disease-specific survival of the European Randomized Study of Screening for 
Prostate Cancer (ERSPC) prevalance screen cohort with the observed PCa- specific mortality of Dutch 
males diagnosed at the age of 60-74 yr during four different time periods [186].
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table 3 - Distribution of cases by received treatment and in three prognostic groups
Prognostic 
group [184] Cause of Death
 Alive PCa death Intercurrent death Total
Favourable
 
 
 
 
RP 212 1 10 223
RT 137 0 23 160
 WW 69 0 6 75
 ET 2 0 0 2
Total 420 1 39 460
Intermediate
 
 
 
 
 
 
 
RP 109 1 9 119
RT 133 1 22 156
WW 13 0 2 15
ET 1 0 0 1
Total 256 2 33 291
High risk
 
 
 
 
 
 
 
RP 54 2 1 57
RT 135 9 30 174
WW 9 0 1 10
ET 12 6 2 20
Total 210 17 34 261
Legend
ET: endocrine treatment; PCa: prostate cancer; RP: radical prostatectomy; RT: radiotherapy; WW: watchful 
waiting.
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Fig. 3 – Prostate cancer-specific survival of high-risk prostate cancer patients (n = 261).
Fig. 3 – Prostate cancer-specific survival of high-risk prostate cancer patients (n = 261). 
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table 4 Uni- and multivariate analysis of prostate cancer characteristics on overall survival (n = 1012)
Univariate Multivariate 
 HR 95% CI HR 95% CI
Lower Upper p value Lower Upper p Value
Age (yr) 1.07 1.03 1.11 <0.001 1.05 1.01 1.09 0.013
PSA (ng/mL) 1.00 0.99 1.01 0.103 1.00 0.99 1.01 0.824
PSA group 0-4*    
4-10 0.73 0.48 1.12 0.149 0.68 0.43 1.07 0.094
>10 1.13 0.71 1.79 0.613 0.77 0.45 1.35 0.366
Charlson score 0*   
1 1.90 1.25 2.88 0.003 1.60 1.05 2.45 0.029
2 3.22 2.06 5.05 <0.001 3.08 1.95 4.86 <0.001
T stage T1C*  
T2 1.29 0.83 2.02 0.264 1.18 0.74 1.90 0.486
T3 T3 2.14 1.30 3.51 0.003 2.07 1.09 3.93 0.026
T4 T4 2.29 0.55 9.60 0.258 1.68 0.30 9.50 .0555
Gleason score  ≤ 3+3*  
 3+4 1.17 0.77 1.78 0.467 0.96 0.56 1,63 0.876
 4+3 1.39 0.34 5.79 0.648 0.82 0.19 3.52 0.789
 ≥4+4 2.76 1.72 4.12 <0.001 2.10 1.05 4.22 0.036
Prognostic Group 
[184] Favourable*
 
Intermediate 1.22 0.77 1.92 0.394 1.04 0.57 1.87 0.906
High risk 2.15 1.41 3.27 <0.001 0.87 0.40 1.89 0.723
Legend
HR: hazard ratio; 95%CI: confidence interval.
* Reference group to which other groups are compared. The reference group per definition has a HR of 1.
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DIsCussIon
Overall Survival
The 6-yr overall survival rate of 83.3% of this report concurs with the report of Holmberg 
et al. [108], which showed that 115 of 695 (16.5%) patients treated with either RP or 
palliative ET, died during a median follow-up of 6.2 yr. The finding that observed overall 
survival for cases was initially better than expected overall survival for Dutch males is in 
line with a recent report from Otto et al. [187]. These authors showed that, after an aver-
age follow-up of 2.8 yr of all randomized cases in the ERSPC, section Rotterdam, overall 
survival was statistically significantly better, compared to the general Dutch population. 
This observation seems to hold ground during the first 60 mo after diagnosis, even in 
the subgroup of cases diagnosed with PCa, and may be due to “healthy screenee bias”. 
With increasing follow-up this advantage gradually disappeared as the observed overall 
survival curve approximated the expected overall survival. 
Disease specific survival
The 97.6% 5-yr overall disease-specific survival found in this screen cohort is in line with 
recent international reports [63, 188, 189] for localized PCa in the PSA era. The small 
number of cases with advanced disease and a worse disease-specific survival had only 
minimal impact on the overall disease-specific survival. The 5-yr disease-specific survival 
of the cohort of males aged 60 to 75 yr from the northern part of the Netherlands was 
82% for males diagnosed between 1996 and 1998. However, this cohort cannot be 
considered to be identical to the control group of the ERSPC; thus, this finding should 
be interpreted with great caution because it is subject to several biases. A comparison 
with the real ERSPC control group at this time is prohibited by obvious trial rules and is 
not possible because these data are still blinded. The survival curve of the screen cohort 
with high-risk PCa, as shown in Fig. 3, is calculated with the use of the Kaplan-Maier 
method and is positively biased by lead-time, length-time and overtreatment, which 
are inherent to screening [4, 94, 95, 97]. The Kaplan-Maier analysis is not the most 
appropriate method to evaluate the effect of screening on disease-specific survival 
because the number at risk decreases with intercurrent mortality and thus influences 
the curve. Still the Kaplan-Maier technique was chosen because those studies, reported 
in the literature of men who were recruited in the PSA era, also used this method [188, 
189]. Differences between curves do not provide treatment comparisons but most likely 
reflect the impact of patient selection. No quantitative statistics were therefore applied.
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The prevalence round of the ERSPC, section Rotterdam, is associated with a mean over-
diagnosis rate of 48.7%, and a mean lead-time of 9.1 yr for males aged 55 to 75 yr [4] 
(personal communication). This finding means that half of the screen detected cancers 
in Rotterdam would not have lead to clinical symptoms, even if they had not been de-
tected, and that the PCa diagnosis is forwarded in time on an average of 9 yr. The impact 
of forwarding the diagnosis in time with screening could be reflected by the observa-
tion that, in the screened population 20 (2.0%) patients died of PCa, compared with 47 
(6.8%) PCa deaths in the report of Holmberg et al. [108], where most of the patients were 
clinically diagnosed. Treatment of an overdiagnosed patient will false-positively favour 
disease-specific survival because overdiagnosed men by definition have a 100% disease 
specific survival rate. Moreover lead-time could suggest an increased disease-specific 
survival, even if an early diagnosis and subsequent treatment do not alter disease-
specific survival prospects. Another uncertainty in this study, which will not be present 
in the final evaluation, is that the causes of death were not independently reviewed. 
Often a death certificate is not filled out by the attending physician because > 50% of 
deaths occur outside office hours [89], which could result in a reported cause of death 
that differs from the clinical picture [190]. Comparing cause of death of medical hospital 
patient charts with information on the death certificate in 201 patients who died of 
PCa Albertsen et al. [191], found a discrepancy of 10 - 20%, indicating the need for an 
independent committee reviewing the causes of death. 
Furthermore the extent of opportunistic screening for PCa in the control population 
(contamination) will influence this comparison because a higher contamination rate will 
decrease the difference between both groups and influence the statistical power [5]. In 
a recent report the effective contamination, defined as an elevated PSA test prompting 
a prostatic biopsy, within the control arm of the ERSPC Rotterdam was calculated to be 
7%; this led to a diagnosis of PCa in 3% [192]. Although exact numbers for contamina-
tion for this group are not available it can be assumed that contamination in this region 
was lower because PSA testing was done less frequently in the rest of the Netherlands, 
compared with the patients included in the trial during 1997 and 2000 [192]. The dis-
ease-specific survival rates of the different cohorts of Dutch males diagnosed with PCa 
between 60 and 74 yr of age increased with time (fig. 2B), which could be explained by 
improved treatments strategies and also by the production of lead-time due to increas-
ing use of PSA-based testing in the Netherlands. Survival curves for males diagnosed 
between 1992 to 1998 in the surrogate control cohort dropped faster initially, compared 
with the screen cohort; however, with extended follow-up they show a stabilizing trend. 
The initial drop reflects the fact that, around 20% of the males in this “control” cohort had 
clinical stage T4 disease at diagnosis [186], compared to 1.1% in the screen cohort, while 
the subsequent stabilizing trend mirrors the relatively favourable prognosis of most PCa 
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patients [75, 86]. If these projections are correct, the cumulative disease-specific survival 
will continue to increase but at an invariably decreasing rate. When all these observa-
tions and biases are taken into consideration, the estimated 10-yr follow-up for the final 
evaluation of the ERSPC trial may be too short. 
Regardless of whether one is in favour or opposed to PCa screening, patients currently 
diagnosed with PCa have a longer life expectancy attributable to lead-time, which is 
bound to go accompanied with a rise of mortality attributable to competing causes, 
especially in patients with favourable PCa characteristics [193]. This favourable group 
will have the highest rate of overdiagnosis, and the patients might not only be bur-
dened unnecesarily with the diagnosis of PCa but might even suffer from side-effects 
after treatment. PCa screening in the general population should not be advocated until 
an effect of PCa mortality has been shown and reliable tools to identify the lethal but 
curable from the overdiagnosed cancers become available. If screening is desirable, the 
decision should be made after objective information has been provided, explaining the 
pros, cons and uncertainties associated with PCa screening. 
ConCLusIons
Although the ERSPC was not designed originally to compare treatment modalities, pre-
liminary overall and disease-specific survival results reflect current trends in literature. 
Patients with screen detected PCa are very unlikely to die of PCa within 5 yr, and had a 
better disease-specific survival, compared with the simulated control cohort. Because of 
the limited number of PCa deaths and the biases associated with PCa screening, a 10-yr 
follow-up period of the final evaluation of the ERSPC may be too short. 
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This important paper by De Vries and colleagues contributes to the increasing evidence 
about survival rates when considering prostate cancer natural history and therapy op-
tions. This study has been performed in the context of the European Randomized Study 
of Screening for Prostate Cancer (ERSPC).We are aware that all participant centers in this 
study follow a strict protocol in all phases of the screening detection process, and also 
with the assignment of causes of death. Local and multicenter committees exert a close 
monitoring for all those processes. In this paper, screening detected prostate cancer 
patients have a 97% chance of avoiding prostate cancer death after 5 years. Although 
five year survival rates are somewhat preliminary when considering screening detected 
cancers, results of overall and disease- specific survival are in line with the existing 
literature, either when radical prostatectomy [195], radiation therapy [196] or watchful 
waiting [85] are considered. Again, Gleason score seems to establish the difference with 
regard to outcomes, no matter which therapy option is chosen. Unfortunately, there 
is still much work to do in the field of localized prostate cancer. No discussion that 
Gleason score (and other tools) may help to identify the highest risk cases, but even 
more has to be done with regard to therapy. First, differences between therapy options 
(aggressive or conservative) to date have shown to be small in terms of survival [85, 195, 
196]. Second, when a randomized trial with a design like ERSPC needs a sample size of 
nearly 200,000 recruited men to demonstrate a potential survival benefit between the 
active way (screening tests and therapy) and the conservative way (no tests, hence no 
therapy), one must consider the possibility that the real survival difference underlying in 
the target population, if existing, may be not so important as many believe.
Do We Need the Final Results of the ERSPC Trial?
Peter Albers 
Department of Urology, Klinikum Kassel GmbH, Mönchebergstraße 41-43, D-34130 Kassel, 
Germany
European Urology 51 (2007) 291–292
The oncologic community eagerly awaits the final results of the two important inter-
national screening studies for prostate cancer (Prostate, Lung Colorectal and Ovary 
[PLCO] and European Randomized Study of Screening for Prostate Cancer [ERSPC]). In 
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the report by de Vries et al.[197] in the current issue of the journal, the investigators of 
the ERSPC trial publish for the first time results regarding overall and disease-specific 
survival in the screening arm of the Rotterdam section of the trial compared to historical 
controls. The 1,014 patients with prostate cancer detected by screening are compared 
with a control group from the Dutch cancer registry of the same region. After a median 
follow-up of 5 yr, only 20 patients (2%) had died from prostate cancer. The comparison 
with the control group of patients diagnosed with prostate cancer between 1996 and 
1998 reveals a difference of 15.6% in favour of the screened population. Of importance, 
this control group is not at all identical with the ERSPC control group. However, the 97.7% 
rate of disease-free survival of the 1,014 patients is in line with the currently published 
rates in patients with localised disease [198]. The authors conclude that patients within 
a screening program have a higher overall survival, which is not surprising because 
the patients see physicians more frequently. They further conclude that patients with 
screening-detected cancers are most unlikely to die from prostate cancer within 5 yr. 
This again is not surprising because the ERSPC investigators have already stated that the 
rate of favourable tumours within screening-detected cancers is much higher compared 
to the control group [199]. Therefore, this effect is completely explained by lead-time 
bias. Their last conclusion is that due to the limited number of prostate cancer deaths 
because of the high numbers of favourable cancers, the final evaluation of the ERSPC 
program may take longer than 10 yr. This, of course, is disappointing for the urologic 
community. This conclusion describes the problems of a trial that started randomisation 
in 1993 and finished enrolment in 1999. Within this time period, the 5-yr disease-specific 
survival rates of prostate cancer patients had improved significantly. This is nicely shown 
in Fig. 2B of the article [197] in the current issue. From an approximately 70% disease-
free survival (DFS) rate in the population 1988–1991, this percentage increased to 82% 
DFS for the population 1996–1998 and 88% in the population diagnosed at the end of 
the enrolment (1999–2001). The DFS of the ERSPC control group is not revealed yet for 
obvious reasons, but the main problem will be that there is an increasing contamination 
of the control group by prostate-specific antigen (PSA) testing from the early 1990s to 
2000. In the final years of the enrolment, the control group certainly did not differ from 
the screened group as it did 6 yr before. This may diminish the difference in DFS rates. The 
second problem may be the high rate of detection of favourable tumours by screening 
as described earlier [182, 199]. The third problem is the high rate of treatment in patients 
who may be candidates for active surveillance. At the time when the trial started, only 
a few patients were offered active surveillance. After the publication of the Canadian 
group regarding the favourable results of surveillance, this treatment strategy emerged 
[200]. Nearly one third of patients in this ERSPC group with screening-detected cancers 
would have been candidates for active surveillance [201]. However, 90% of patients 
chose active treatment with a somewhat higher chance of side- effects. For example, 
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of the 20 patients who have died from prostate cancer in this publication, 4 died after 
radical prostatectomy but 2 of these 4 died perioperatively. Seventeen of 20 patients 
who died from prostate cancer had highrisk features. Only 10% (n = 100) of patients 
voted for watchful waiting. Therefore, the changing treatment options in the last 5 yr 
will certainly become a problem in the interpretation of the ERSPC trial results. If the 
trial fails to show a superiority of screening in terms of mortality, people will argue that 
in recent years many had an opportunistic screening (currently an estimated 7%). If the 
trial shows the superiority of screening in terms of mortality, people will argue whether 
a rigorous active surveillance strategy instead of a mere control group would be the 
easiest solution for the problem and that this strategy had been underused during the 
time of enrolment. With an even longer follow-up, the problems will not disappear. Of 
importance, this trial delivers repeatedly valuable information on the changes of pros-
tate cancer management in the 1990s with strong implications for treatment. Before the 
final results will be published, this trial yields results that influence treatment decisions 
of today, for example, baseline PSA, frequency of PSA values to exclude progression, and 
cut-off levels of PSA. Nearly all patients who are in danger of dying from prostate cancer 
within 5 yr have Gleason 4 + 4 or higher differentiation, only 15% of patients with favour-
able parameters and active surveillance need deferred treatment, and thus the overall 
disease-specific survival at 5 yr currently is nearly 100% [198]. Screening or not is mainly 
a health policy issue. For most men, an early PSA value at the age 40–45 yr is important 
[202]. With standardisation in the diagnosis and implementation of active surveillance, 
most of the important problems appear in the patients with locally advanced or meta-
static disease. During the last years the number of patients with the primary diagnosis 
of a metastatic prostate cancer has decreased. Thus, at the time when the screening 
results are available, the potential screening population will have changed with most 
of the men already knowing their PSA value and acting accordingly. The ERSPC trial has 
already provided the uro-oncologic community with such valuable information that the 
planned publication should not be delayed. Remember the Holmberg data that were 
derived from a completely different staging era when the diagnosis by transurethral re-
section was common [195]. At the time of publication this time lag certainly influenced 
the interpretation of the results in terms of translation to the current clinical situation. 
This should be kept in mind if the conclusion is drawn that the final results of the screen-
ing trials will take longer then expected. 
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abstRaCt
objectives
To evaluate the adjuvant clinical use of [-2]precursor prostate-specific antigen ([-2]pPSA), 
which is associated with prostate cancer (PCa), and “benign” PSA, related to benign pros-
tatic hyperplasia, in selecting a treatment strategy in patients with screen-detected PCa. 
Methods
Research-use immunoassays (Beckman Coulter) were used to measure [-2]pPSA, sum 
[-7, -5, -4, and -2]pPSA, and benign PSA from the frozen serum of participants from 
the screen arm of the European Randomized Study of Screening for Prostate Cancer, 
section Rotterdam, diagnosed with PCa with a serum PSA level lower than 15 ng/mL. 
We compared men with relatively benign PCa (Epstein’s criteria; group 1) and men with 
arbitrarily defined aggressive PCa characteristics (Gleason score greater than 4 + 4 and 
more than four cores with PCa invasion or pT3C disease; group 2). 
Results
The data of 61 patients were evaluated. The median age in both groups was 68 years. 
Total PSA performed best in a univariate analysis, although in the multivariate analysis, 
the combination of pPSA and percent free PSA could correctly predict 95.5% of group 
1 and 82.4% of group 2. The pPSA and percent free PSA forms remained statistically 
significant in the multivariate analysis of a subgroup of 30 participants normalized for 
PSA level and prostate volume; combined they correctly identified 89.5% and 54.5% of 
patients identified as having relatively favourable and aggressive PCa characteristics, 
respectively. 
Conclusions
Adjuvant clinical use of pPSA over traditional parameters in selecting treatment strate-
gies for men with PCa cannot yet be definitely determined. However, the promising 
results in a subgroup analysis warrant further investigation.
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IntRoDuCtIon
In the continuing quest for a better, more reliable, and informative marker for prostate 
cancer (PCa), varying prostate-specific antigen (PSA) derivatives have been evaluated 
and tested for clinical utility. Recently discovered molecular precursors forms of PSA 
(pPSA), appear to correlate with PCa [41, 51, 209]. Native pPSA contains a 7 amino acid 
N-terminal pro-peptide, but multiple forms of pPSA with truncated pro-peptides are 
found in serum [34, 35, 44]. In vitro, the most stable of the five currently identified pPSA 
forms is [-2]pPSA, the PSA molecule plus two precursor amino acids [40]. The [-2]pPSA 
form also shows the most cancer specificity by immunostaining [210]. Pro-PSA together 
with benign PSA (BPSA) and inactive PSA, constitute the free PSA fraction of PSA (FPSA) 
[51]. Although BPSA is not directly associated with PCa, it was significantly elevated in 
biopsy-negative men with a raised PSA level, and might thus be a marker for benign 
prostatic hyperplasia [46, 51]. In this study, we evaluated the adjuvant clinical value of 
the combination of [-2]pPSA and BPSA in predicting the PCa characteristics in patients 
with screen-detected PCa using research assays (Beckman Coulter, for research use only; 
not intended for use in diagnostic procedures). We hypothesized that a high [-2]pPSA 
level and a low BPSA level would reflect relatively poor prognosis PCa, with the reverse 
associated with relatively favourable PCa prognostic factors. If true, this [-2]pPSA / BPSA 
ratio could then be used in determining therapy. 
MateRIaL anD MethoDs
Research-use immunoassays (Beckman- Coulter, San Diego, Calif ) were used to retro-
spectively estimate the [-2]pPSA, sum [-7, -5, -4 and -2]pPSA (designated as pPSA) [209], 
and [44] levels, in addition to total PSA(tPSA) and FPSA from the frozen serum of men with 
histologically proven, screen-detected PCa from the screen arm of the European Ran-
domized Study of Screening for Prostate Cancer, section Rotterdam. The blood samples 
of participants were assayed for tPSA within 3 hours and the remaining serum stored at 
–80 °C. The samples were stored on dry ice during shipment (Biologistic Services, The 
Netherlands, www.biologistic.nl) to San Diego where they were processed. The condi-
tions and algorithm of the European Randomized Study of Screening for Prostate Cancer 
have been described in detail elsewhere [211-213]. In brief, after giving written informed 
consent, 21,210 of 42,376 men aged 55 to 74 years were randomized into the screening 
arm. The participants underwent three screening tests: PSA measurement, digital rectal 
examination, and a transrectal ultrasonography. The biopsy indication was set at a PSA 
level of 4.0 ng/mL or greater, or suspicious findings on digital rectal examination or tran-
srectal ultrasonography. After April 1997, a PSA level of 3.0 ng/mL or greater prompted 
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sextant biopsy. Lateral sextant biopsies were taken in line with the recommendations of 
Eskew et al. [131]. In the case of a hypoechogenic lesion on transrectal ultrasonography, 
a seventh, lesion-directed biopsy, was taken. Because of two side studies, during the 
second round some men were also offered biopsy if they had a PSA level of 1.0 to 2.9 
ng/mL. Clinical staging was done throughout the whole study according to the Interna-
tional Union Against Cancer TNM classification of 1992 [81]. The prostate biopsy cores 
are labeled and processed individually. The exact processing of lateral sextant biopsy 
results has been described elsewhere [203]. Patients with relatively favourable prognos-
tic factors were selected from the group of men initially followed up with a watchful 
waiting policy, using the biopsy-derived criteria of Epstein et al. [150] for minimal PCa 
(T1c disease, PSA density (PSAD) less than 0.15 ng/mL/cm3, no Gleason pattern 4, less 
than 50% invasion per core, and 2 cores maximum with PCa invasion). Patients from the 
prevalence screen with a biopsy Gleason score of 4+4 or greater and more than four 
biopsy cores with PCa invasion or pathological Stage T3c were arbitrarily considered to 
represent poor prognosis PCa. Men with a PSA level at diagnosis of greater than 15 ng/
mL were excluded to minimize the difference of PSA fractions due to tPSA values. Figure 
1 shows a flowchart of the current study. To exclude a possible tPSA to volume bias, 
a second analysis for cases in the 4 to 10 ng/mL PSA range combined with a prostate 
volume (PV) smaller than 60 cm3 was performed. 
Patients were selected from the original watchful waiting cohort and the previously 
defined aggressive PCa cohort. The patients in the favourable group all had clinically T1c 
disease, combined with one biopsy core invaded with well-differentiated PCa, (Gleason 
3+3 or lower). In both analyses, absolute total values of all PSA subforms, as well as the 
fractions of the PSA subforms, in FPSA were compared. 
Statistical analyses were performed using the commercially available Statistical Pack-
age for Social Sciences software, version 12.0 (SPSS, Chicago, Ill). Two sided P values 
were calculated with the Mann-Whitney U tests for all variables. A significance cutoff 
of 5% was used. In the initial analysis only, all PSA derivates were a candidate for entry 
into the forward logistic regression multivariate analysis. TPSA, PV, and PSAD were not 
candidates, because selection for the favourable prognostic group was partly based on 
the PSAD. In the subgroup analysis, PSA, and all PSA subforms were candidates.
ResuLts
Of 201 patients with screen-detected PCa initially treated on a watchful waiting policy, 
44 had favourable prognostic characteristics. The data of PSA, additional FPSA and FPSA 
subforms, were compared with the results of 17 patients who had the previously defined 
aggressive PCa characteristics. The results for both groups, with univariate analysis-
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Legend Figure 1: Flowchart of European Randomized Study of Screening for Prostate Cancer. ∧ Until June 
2002. * Epstein criteria [150] # arbitrarily defined criteria  
Group 1 (n=45) 
Favourable prognosis 
PCa (cT1C, PSAD 
<0.15, Gleason ≤ 3+3, ≤ 
2 biopsy cores with PCa 
invasion and ≤ 50% PCa 
invasion per core)* 
Group 2 (n=17)           
Poor prognosis PCa 
(Gleason ≥ 4+4 combined 
with pT3C and greater, or ≥ 
4 biopsy cores with PCa 
invasion)# 
Subgroup analysis 
(PSA 4-10 ng/mL and prostate volume ≤ 60 cm3) 
Group 3  
Favourable prognosis PCa (n=19) 
(cT1c, one positive biopsy core 
and Gleason score ≤ 3+3)# 
Group 4 
Poor prognosis 
PCa as group 2 
(n=11) 
ERSPC section Rotterdam (n= 42,376) 
Screen arm (n=21,210) Control arm (n=21,166) 
Prostate cancer diagnosis  no prostate cancer diagnosis 
Initial watchful waiting policy (n=210)^ Immediate treatment (n=1259) 
Legend Figure 1: Flowchart of European Randomized Study of Screening for Prostate Cancer. * Until June 
2002. * Epstein criteria [150] # arbitrarily defined criteria 
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related P values are shown in table 1. The differences in tPSA, planimetric PV, PSAD, and 
absolute levels of FPSA, [-2]pPSA, BPSA, and pPSA were statistically significant between 
groups. After calculating the different ratios of the FPSA subforms in FPSA, only the 
difference in the fraction [-2]pPSA in FPSA (P =0.001) remained statistically significant. 
As expected, the difference in the percent FPSA (%FPSA) was statistically significant be-
tween the two groups. None of the PSA derivates alone could outperform tPSA, because 
the tPSA had the best ROC curve at any point (data not shown). The [-2]pPSA to BPSA 
ratio reached borderline statistical significance (P = 0.043). The statistical difference of 
tPSA and PV was at least partially due to the use of a cutoff value for the PSAD (less 
than 0.15 ng/mL/cm3) for the favourable group, who were, therefore, not entered in the 
multivariate analysis. In the multivariate logistic regression analysis, pPSA and %FPSA 
remained statistically significant predictors, with P = 0.001 and P < 0.001, respectively 
(Table 2). In combination, they predicted 42 of the 44 “favourable” patients (sensitivity 
95.5%) and missed 3 of 17 patients with poor characteristics (specificity 82.4%). 
To minimize the influence of tPSA level and PV on the PSA subforms, we did a subgroup 
analysis in the group of men with PSA level between 4 and 10 ng/mL and a PV smaller 
than 60 cm3. The 19 patients in group 3 were compared with the 11 men with poor prog-
nostic PCa characteristics. Table 3 shows the results of the subgroup analysis. Now only 
the absolute value (in ng/mL) of pPSA, as well as its fraction in FPSA and the [-2]pPSA/
BPSA ratio, were statistically significantly different between groups (P= 0.030, P=0.027, 
and P=0.033, respectively). PSAD remained statistically significantly greater in the poor 
table 1 Patient characteristics at diagnosis
Favourable PCa (n= 44) Poor PCa (n = 17) Total (n=61)
Median Minimumimim Maximum Median Minimum Maximum Median p value 
Age (yr)  68  57  75  68  58  74  68  0.778
PSA (ng/mL)  4.0  1.4  9.3  7.0  3.5  14.8  4.5  <0.001
Prostate volume (cm3)  45.60  21.40  129.50  34.50  19.90  68.20  42.40  0.005
PSAD  0.08  0.03  0.15  0.21  0.10  0.53  0.09  <0.001
FPSA  0.66  0.29  2.69  0.78  0.43  1.51  0.72  0.032
[-2]pPSA  0.032  0.013  0.251  0.065  0.018  0.103  0.037  <0.001
pPSA  0.273  0.077  0.790  0.420  0.148  0.742  0.290  0.006
BPSA  0.172  0.035  1.233  0.264  0.095  0.541  0.199  0.043
[-2]pPSA/BPSA ratio  0.181  0.027  0.966  0.228  0.082  0.428  0.211  0.043
%FPSA  0.165  0.093  0.297  0.109  0.044  0.248  0.153  <0.001
pPSA / FPSA ratio  0.430  0.175  0.817  0.503  0.283  0.830  0.453  0.054
[-2]pPSA/FPSA ratio  0.050  0.019  0.290  0.082  0.041  0.122  0.058  0.001
BPSA/FPSA ratio  0.284  0.122  0.961  0.284  0.181  0.566  0.284  0.520
Legend: PCa: prostate cancer; PSA: prostate-specific antigen; PSAD: PSA density; FPSA: freePSA; [-2]pPSA: 
fraction of precursor PSA; pPSA: precursor PSA; BPSA: benign PSA; %FPSA: percent FPSA.
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prognostic group (P=0.033). In the forward multivariate logistic regression analysis, only 
the entering PSA and PSA subforms, pPSA and %FPSA, remained significant predictors 
and together reached a sensitivity of 89.5% with a specificity of 54.5% (Table 2). 
CoMMent
PCa remains an unpredictable disease capable of killing patients. In the current PSA 
screening era, however, the vast majority of detected cancers are well differentiated 
and clinically organ confined and can be treated with a curative intent [77]. However, 
table 2. Multivariate analysis results
Included p-value Sensitivity (%) Specificity 
(%)
PPV 
(%)
NPV 
(%)
Odds 
ratio
95 CI
“Favourable” vs.      
“poor”
pPSA     
%FPSA   
 0.001 
<0.001 
95.5%     
(42 of 44)
82.4%     
(14 of 17)
93.3% 87.5% 1.0*106 
<0.001 
414 - 2.4*108      
7.6*10-29 - 
1.5*10-9 
subgroup 
“favourable” vs. 
“poor”
pPSA    
%FPSA
0.015 
0.053
89.5%     
(17 of 19)
54.5%      
(6 of 11)
77.3% 75% 2.5*104 
<0.001
7.5 - 8.7*107   
1.5*10-18 - 1.3
Legend: PPV: positive predictive value; NPV: negative predictive value; CI: confidence interval; other 
abbreviations as in Table 1
table 3. Patient characteristics in the PSA 4-10ng/ml range
  “Favourable” PCa (n=19) “Poor” PCa (n= 11)   Total  
  Median Minimum Maximum Median Minimum Maximum Median
p value 
 (Two-
Tailed)
Age (yr) 68 57 75 68 58 74 68 0.591
PSA (ng/mL) 5.8 4.1 8.7 6.4 5.0 9.5 6.2 0.106
Prostate volume (cm3) 39.9 22.7 58.0 32.6 20.6 46.3 35.2 0.162
PSAD 0.15 0.08 0.28 0.20 0.14 0.35 0.17 0.033
FPSA 0.730 0.360 2.380 0.930 0.430 1.510 0.748 0.518
[-2]pPSA 0.049 0.013 0.251 0.067 0.039 0.103 0.051 0.055
pPSA 0.367 0.121 0.696 0.588 0.230 0.742 0.417 0.030
BPSA 0.234 0.122 1.389 0.287 0.095 0.541 0.247 0.813
[-2]pPSA/BPSA 0.196 0.016 0.966 0.308 0.191 0.428 0.231 0.033
%FPSA 0.149 0.041 0.301 0.110 0.069 0.248 0.142 0.189
pPSA / FPSA 0.478 0.055 0.817 0.571 0.360 0.830 0.497 0.027
[-2]pPSA / FPSA 0.054 0.009 0.290 0.082 0.047 0.122 0.068 0.074
BPSA / FPSA 0.301 0.178 0.584 0.247 0.181 0.566 0.287 0.175
Legend as in Table 1.
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because of overdiagnosis, which has been shown to be present in 50% of patients or 
more with screen-detected PCa [4, 95], not all patients with PCa will need immediate 
radical treatment. The decision regarding therapy is often based on predictors estimat-
ing tumour aggressiveness and the patient’s wishes. Commonly used parameters such 
as the biopsy Gleason score, PSAD and clinical stage, although validated and clinically 
useful, are subject to error because of interobserver and intraobserver variability [76, 
141, 214]. A reliable biochemical parameter reflecting tumour characteristics could aid 
both clinicians and patients in more objectively choosing a therapy modality. In this 
study, we evaluated the use of pPSA forms combined with BPSA as a possible future 
aid in making treatment decisions. Bangma et al. [215] investigated the value of [-5,-7]
pPSA and human kallikrein-2 but not [-2]pPSA and BPSA as possible serum markers for 
PCa grading. Using a different assay system for [-5,-7]pPSA [215], the investigators did 
not find any correlation between these serum markers and the pathological grade or 
stage. Catalona et al. [42], and Sokoll et al. [216] initially demonstrated that the ratio of 
pPSA in FPSA (%pPSA) significantly increased the specificity for cancer detection in the 
2 to10 ng/mL PSA range and outperformed tPSA and %FPSA. The measurement of [-5,-7]
pPSA alone, however, did not add significant clinical utility in those studies, in agree-
ment with Bangma et al. [215]. In a more recent study, Catalona et al. [43] reported the 
tumour characteristics of the same cohort and determined that %[-2]pPSA was the best 
discriminator to identify aggressive cancers in the 2 to 4 ng/mL PSA range and %pPSA 
was the best predictor in the 4 to 10 ng/mL range [43]. The investigators defined an 
aggressive cancer as one with a biopsy or pathological Gleason score of 7 or greater or a 
pathologic stage T3. The median values for %pPSA in 4 to 10 ng/mL range in the current 
report were greater than those observed by Catalona et al. [43] and Sokoll et al. [216], 
which could be explained by the different selection criteria used. The differences in the 
absolute values of FPSA, pPSA forms, %FPSA, and %pPSA were statistically significant 
between groups in the current initial analysis, as was the tPSA. The combination of pPSA 
and %FPSA correctly predicted 42 of 44 men with favourable PCa and 14 of 17 patients 
with arbitrarily defined poor PCa characteristics (Table 2), This impressive result, how-
ever, could also be attributed to the significantly greater tPSA and lower PV in the poor 
characteristics group, because both parameters can influence the pPSA and BPSA levels 
[48, 215]. Moreover, by using the Epstein criteria to select the group of patients with 
relatively favourable PCa characteristics, a PSA to PV bias was introduced. 
To test the hypothesis that the combination of [-2]pPSA and BPSA could differentiate 
between relatively favourable and poor PCa characteristics, a subgroup analysis of 
patients with comparable tPSA values and PV at diagnosis was done. Although the num-
bers were limited, this analysis showed a statistically significantly lower [-2]pPSA/BPSA 
ratio (P=0.033) in men with favourable PCa characteristics compared with those with 
poor PCa characteristics, in line with our hypothesis. The pPSA and %pPSA remained 
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significantly greater in the poor prognostic subgroup. In the multivariate analysis, the 
combination of pPSA and %FPSA reached a sensitivity of 89.5% and specificity of 54.5%. 
This means that 17 of 19 men with arbitrarily defined favourable PCa characteristics 
were correctly identified as having relatively favourable prognostic PCa characteristics 
on the basis of a combination of these serum markers. Owing to the low specificity of 
the test, the positive predictive value of the test was 77.3%, meaning that roughly three 
quarters of the patients identified as “favourable” by this marker combination did have 
favourable prognostic characteristics and one quarter actually had “poor” prognostic 
characteristics. Although promising, this result should be interpreted with caution. 
First, the groups were small and arbitrarily defined and compared populations of PCa 
with rather extreme differences in prognostic characteristics. Second, clinical, and not 
pathologic, tumour characteristics were used to design the patient groups, and those 
are known to underestimate the highest cancer grade present in the prostate. Third, 
conserved frozen samples were tested with a research-use assay that may not be as 
robust as fully validated assays. Despite these potential limitations, in our opinion, the 
results warrant further study of these new tumour markers.
ConCLusIons
The adjuvant clinical usefulness of pPSA forms and BPSA in identifying aggressive from 
less aggressive PCa, compared with traditional parameters, cannot yet be definitively 
determined. However, the promising results in a subgroup analysis warrant additional 
study. 
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abstRaCt
Purpose: 
We evaluated prostate cancer (PCa) characteristics at diagnosis and changes in prostatic 
specific antigen (PSA) with time in males with screening detected PCa that was initially 
managed with a watchful waiting policy. 
Materials and Methods: 
Patients with histologically proven PCa and PSA less than 10 ng/mL were selected from 
the European Randomized Study of Screening for Prostate Cancer, section Rotterdam. 
The choice of initiating a watchful waiting policy was patient desire or physician advice. 
PSA slope and PSA doubling time (PSADT) were calculated in patients with 3 or more 
PSA test results available. 
Results:
A total of 191 patients were included. Mean age at diagnosis was 69 years and mean 
PSA was 3.9 ng/mL. Of the patients 92.6% had a Gleason score of 3 + 3 or lower, 133 had 
a follow-up of greater than 12 months (mean 40) and 35 (29.2%) had a negative PSA 
slope. Mean PSADT was 9.7 years (range 0.3 to 155) in 85 males with a positive PSA slope. 
During follow-up 30 patients changed therapy. 
Conclusions: 
Watchful waiting remains a controversial prostate cancer treatment strategy. In select 
screening detected patients with PCa, there appears to be a subgroup with stable or 
even decreasing PSA values with time. These males could profit from a watchful waiting 
policy with possible deferred treatment. Together with conventional tumour parameters 
at diagnosis PSADT and PSA slope during follow-up could be used to monitor tumour 
activity and possibly aid in determining the time of deferred treatment. Further follow-
up is mandatory to validate these results. 
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IntRoDuCtIon
The primary goals of the European Randomized Study of Screening for Prostate Cancer 
(ERSPC) are to show a significant decrease in prostate cancer (PCa) mortality between 
the screening and control arms, and evaluate screening algorithms [88]. The ERSPC was 
not primarily designed to compare different treatment modalities. In the Dutch (Rot-
terdam) screening arm of the ERSPC males with a histologically proven PCa are referred 
to their general practitioner after discussing diagnosis and treatment options during an 
outpatient clinic visit at the study site. Patients are free to choose the treatment modal-
ity as well as the specific health care center. In some select patients the physician of 
choice might not advise immediate radical therapy, while some patients do not desire 
immediate treatment. We outline preliminary results in patients in the screening arm of 
the ERSPC, section Rotterdam with watchful waiting as initial treatment. 
PatIents anD MethoDs
After four pilot studies the ERSPC, section Rotterdam started in June 1994 with a four-
year screening interval. The conditions and algorithm of the ERSPC have been previously 
described in detail [88]. Briefly, 21,210 of 42,376 men 55 to 74 years old were randomized 
into the screening arm after providing written informed consent. Participants under-
went 3 screening tests, namely PSA measurement, digital rectal examination (DRE) and 
transrectal ultrasound (TRUS). Biopsy indication was set at PSA 4.0 ng/mL or greater, or 
suspicious findings on DRE or TRUS. After April 1997, PSA 3.0 ng/mL or greater prompted 
sextant biopsy. Lateral sextant biopsies were performed, in line with the findings of 
Eskew et al. [131]. In case of a hypoechogenic lesion on TRUS a seventh, lesion directed 
biopsy was obtained. Due to 2 side studies during the round 2 some men were also 
offered biopsy in the PSA 1.0 to 2.9 ng/ml range [88]. Patients in the screening arm 
with a histologically proven PCa who had started on a watchful waiting policy between 
September 1994 until August 2002 were selected. Excluded were patients with PSA at 
diagnosis greater than 10 ng/mL due to a lower probability of organ confined disease. 
PSA at diagnosis was determined with the Beckman-Coulter Hybritech Tandem E Assay; 
(Hybritech, San Diego, California). Since January 2000, the Access automated version has 
been used (Beckman- Coulter, Fullerton, California). No statistically significant difference 
was found between these assays in the PSA range of less than 10 ng/mL. Clinical staging 
is done throughout the whole study according to the 1992 UICC TNM classification [81]. 
Prostate biopsy cores are labeled and processed individually [203]. To estimate comor-
bidity status at diagnosis the Charlson score was used [183]. Because follow-up regimens 
varied among local practices, data for this study were collected from semiannual patient 
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chart review for the first 5 years and annually thereafter. Charts were assessed for medi-
cal history, physical examination (DRE), dissemination studies and PSA tests. To minimize 
PSA level outcome differences, the PSA values of other assays were corrected for known 
differences with the Hybritech assay using the regression method of Passing and Bablok 
(see appendix) [204, 205]. Indications and patient characteristics are provided for those 
who changed therapy. To calculate PSA doubling time (PSADT) the base 2 logarithm 
of the PSA value was calculated using the formula, 2log(PSA) = 10log(PSA) / 10log(2) 
[206], and plotted against time since diagnosis (date of PSA measurement to date of 
diagnosis). The linear regression line through these points estimates the PSA slope. The 
doubling time can be calculated as the reciprocal value of a positive slope, while a nega-
tive or decreasing slope represents a PSA half-life. PSA slopes were only calculated in 
patients with 3 or more PSA values acquired prior to a possible therapy change. 
ResuLts 
In the ERSPC screening arm 1,514 males were diagnosed with adenocarcinoma of the 
prostate between September 1994 to August 2002 and 201 were initially managed by a 
WW policy that is 13.3% of all screening detected cancers. We excluded 10 males due to 
a PSA greater than 10 ng/mL at diagnosis. Table 1 shows results in the 10 excluded pa-
tients. Shortly after the PCa diagnosis 1 excluded patient died of a pulmonary embolism 
after tumour nephrectomy.
table 1. Excluded patients with PSA greater than10.0 ng/mL
Patient Age at 
diagnosis
PSA at 
diagnosis 
(ng/mL)
PSA 
density
(ng/mL/ 
cm3)
Gleason 
pattern 
No. pos 
cores
PSADT 
(yrs)
Follow-up 
(mos)
Treatment 
Change
last PSA 
(ng/mL)
1 75.3 24.8 0.27 3+3 1 3.1 89.7 ET after 80.5 mos 1.7
2 74.7 10.4 0.17 3+4 4 4.9 44.6 no change 17
3 73.9 10.3 0.38 3+3 1 9.2 63.4 no change 14
4 71.2 13.1 0.25 3+4 3 -3.0 50.1 EBRT after 19.4 
mos
1.8
5 66.5 315.7 5.80 4+4 3 0.8 85.8 ET after 18.7 mos 1.9
6 72.4 13.2 0.29 3+3 4 9.2 57.4 no change 8.6
7 72.8 16.6 0.15 3+4 4  0.0 no change died
8 74.0 12.0 0.56 3+3 1 4.0 20.9 no change 15.3
9 58.6 55.0 1.82 4+4 7 5.1 28.9 no change 76
10 64.4 11.0 0.22 3+3 2 -6.4 33.0 no change 7.5
legend 
ET= Endocrine Treatment
EBRT= External Beam Radiation Therapy
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Table 2 shows the characteristics at diagnosis of the 191 included males. Of the included 
men 103 were diagnosed with PCa in round 1, including 8 after repeat biopsy 1 year 
later, while 87 were diagnosed in round 2 and 1 was diagnosed in round 3. Mean age at 
diagnosis was 69 years. The majority of concomitant diseases were related to the cardio-
vascular/cerebrovascular systems. In 76 patients (39.8%) the physician suggested WW, 
while 73 patients (38.2%) preferred a watchful waiting policy. In 42 patients (22%) these 
data are not yet available. A total of 32 males (16.6%) had a PSA less than 3.0 ng/mL.
DRE was abnormal in 47 patients (24.6%). Of the patients 28 had T2A, 2 had T2B, 11 had 
T2C and 6 patients had T3 palpable disease, which was T3A in 5 and T3C in 1. 
In 154 men (80.6%) the biopsy Gleason sum was 6 (3+3), while 23 (12%) had a Gleason 
sum of less than 6. One patient had a Gleason score of 4+3, 9 had a Gleason score of 3+4 
and the remaining 4 men had a 4+4 Gleason pattern. A total of 106 patients (88.3%) with 
1 positive core had less than 30% invasion of that core, while 4 (3.3%) had greater than 
50% invasion in that single positive core. Follow-up for 12 months (mean 40, range 13 
to 100) was available on 133 patients and 120 underwent 3 or more PSA tests (median, 
range 3 to 15) before changing therapy. In these patients the mean PSA slope was 0.11 
2log(ng/mL) yearly (median 0.09, range -0.91 to 3.0), which corresponds to a mean 
PSADT of 11.6 years (median 6.9, range 0.3 to 101) in patients with a positive slope. Table 
3 shows the distribution of PSADT, PSA half-life, and related treatment decisions. 
During follow-up 30 patients changed therapy. A total of 20 patients received subse-
quent radiation therapy with curative intent, including 2 who received adjuvant endo-
crine treatment. Five men underwent radical prostatectomy (RP). Five males are being 
treated with endocrine treatment (ET), 2 have other malignancies (urothelial cell carci-
noma and metastasized bladder cancer, respectively) and 1 who progressed to clinical 
T3A stage elected to start endocrine treatment. The remaining patient was intentionally 
scheduled for curative radiation therapy, but computerized tomography guided punc-
tion confirmed PCa metastasis. He has been on luteinizing releasing hormone analogues 
since November 1997 and still has PSA less than 1 ng/mL. The remaining patient uses 
the 5a-reductase blocker finasteride. Median time to treatment change was 19 months 
(mean 27, range 7 to 82) with a mean follow-up after treatment of 27 months (median 
20, range 2 to 86) (table 4). Of the 30 patients with subsequent treatment 1 currently has 
signs of biochemical recurrence. He underwent RP 7 months after diagnosis, when PSA 
increased from 2.4 ng/mL at diagnosis to 3.5 ng/mL. Trigger points for deferred therapy 
were patient desire without signs of biochemical or local progression in 5 males. Two 
males had PSA plus local progression. In 22 males the treating physician interpreted the 
PSA increase with time as biochemical progression, and 1 patient seemed to have local 
progression without PSA progression. 
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table 2. Characteristics at diagnosis in 191 included males
  No. Pts  (%)
Age at diagnosis (mean 68.6 median 69.3):
55-59 8 4.2
60 - 64 33 17.3
65 - 69 64 33.5
70 - 74 82 42.9
Older than 75 4 2.1
Charlson score:
1 or Less 153 80.1
Greater than 1 22 11.4
Unknown 16 8.4
PSA at diagnosis ng/mL ( mean 3.9 median 3.6):
 Less than 4 108 56.5
4-10 83 46.3
PSA density ng/mL/ cm3 (mean 0.11 median 0.09):
 0.15 or Less 154 83.2
Greater than 0.15 37 16.8
Clinical stage:
T1C 144 75.4
T2 41 21.5
T3 6 3.1
No. pos cores:
1 120 62.8
2 43 22.5
3 or Greater 28 14.7
Gleason sum:
6 or Less 177 92.7
7 10 5.2
8 or Greater 4 2.1
Therapy choice:
Physician suggestion 76 39.8
Patient choice 73 38.2
Unknown 42 22.0
Mean follow-up was 40 months (median 37, range 13.5 to 99.8 in 133 patients with greater than12 
months of follow-up.
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During follow-up 6 patients in the overall group have died of intercurrent causes. 
None have died of prostate cancer, as coded by the independent Causes of Death Com-
mittee [88].
table 3. PSADT in patients with 3 or more PSA test before treatment change and PSA half-life in those 
with negative slope
    no.treatment Change
PsaDt (yrs) no yes total (n=) total (%)
0 - 1.99 1 4 5 4.2
2 - 2.99 5 4 9 7.5
3 - 3.99 5 2 7 5.8
4 - 4.99 9 3 12 10.0
5 - 9.99 20 2 22 18.3
10 - 19.99 17 2 19 15.8
> 20 9 2 11 9.2
66 19 85 70.8
 
Psa half-life (yrs)
> 10 17 1 18 15.0
5 - 9.99 7 7 5.8
3 - 4.99 8 8 6.7
1 -2 2   2 1.7
subtotals 34 1 35 29.2
Total 100 20 120 100.0
table 4. Characteristics of patients with subsequent treatment.
Median RP Median RT Median ET Totals
No. Pts. 5 20 5 30
Age at diagnosis (years) 68 67.5 73.7 67.7
PSA at diagnosis ng/mL (range) 3.4 (2.4 - 7.3) 4.8 (1.4 - 7.6) 3.6 (3.1 - 5.2) 4.4 (1.4 - 7.6)
Months before treatment 9.1 (6.9 - 53) 19.1 (12.0 - 58.6) 23.9 (14.8 - 60.5) 19.1 (6.9 - 60.5)
Mos follow-up after treatment 
(range) 47.5 (4.7 - 85.5) 19.0 (2.9 - 57.2) 8.2 (0 - 55.7) 20.5 (0 - 85.8)
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DIsCussIon
Organ confined adenocarcinoma of the prostate can be managed in 3 ways, namely 
by surgery, radiation therapy or watchful waiting. In surgery and radiation therapy the 
goal is to eliminate the primary tumour. However, in this effort normal structures are 
sometimes damaged, and unwanted side effects can occur. The combination of slow PCa 
progression in most screening detected cases [4, 94], the suspected overdiagnosis of 
PCa in this opportunistic (PSA) screening era [4], and these possible side effects explain 
renewed interest in watchful waiting [108, 122, 145]. The rationale of watchful waiting 
should be to avoid unnecessary treatment with its inherent side effects and costs in 
patients with PCa, who are not likely to progress to clinical disease during their lifetime, 
while offering these select patients a possible cure later. Thus, the key to successful 
watchful waiting is based on 2 pillars. 
It must become possible to identify patients with organ confined PCa who have latent 
or minimal PCa and are not likely to progress or who might even never have symptoms 
of the disease. 
Objective and reliable parameters of PCa activity must become available to monitor 
this cohort not to lose the opportunity of treatment with curative intent when required 
or desired. 
In the literature PSA at diagnosis less than 10 ng/mL, clinical stage T2A and a Gleason 
score of 3+3 or lower are usually used to identify males with favourable PCa characteris-
tics. In the current study 161 males (84%) had such favourable characteristics. 
Although earlier studies suggested an advantage of RP over radiotherapy [188], recent 
reports show similar 5 and 8-year biochemical-free survival rates of up to 90% for either 
therapy modality in patients with favourable prognostic PCa characteristics [77, 189]. 
Although biochemical-free survival is a surrogate endpoint, these impressive results 
might well be positively biased by a number of males with screening detected PCa that 
might not have become clinically apparent during the normal lifetime [4, 95], since by 
definition overtreatment has a 100% disease specific survival rate. 
Carter et al. selected 81 patients with presumed small volume cancers [145] based 
on the Epstein criteria, T1C, PSAD 0.15 ng/ml/cm3 or less, 2 or fewer cores with can-
cerous invasion, less than 50% cancer invasion in any core and no Gleason pattern 
table 5. PSADT in patients with positive slope
  No change Change Totals
Mean yrs* 12.6 8.0 11.6
Median (range) 7.9 (1.9-101) 3.4 ( 0.3-44 ) 6.9 ( 0.3-101 )
total (n) 66 19 85
* p= 0.006
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greater than 3 for watchful waiting [150]. Follow-up consisted of semiannual PSA tests 
and annual repeat biopsy (greater than 12 cores). Of 25 patients with progression on 
prostatic needle biopsy 12 had curable cancers after RP [145]. Of the 100 males in this 
study complying with Epstein selection criteria 2 underwent RP and 5 received radiation 
therapy. In the Rotterdam region repeat prostate biopsy to evaluate histological PCa 
characteristics is not a routine investigation. Still, during follow-up in the current study 
16 patients underwent repeat biopsy. In 7 sextant biopsies PCa histology was found, 
which led to subsequent treatment in 2 males. The remaining 9 biopsies did not show 
histological evidence of PCa. Apart from histological progression, PSA tests can be done 
during follow-up in patients with PCa. This is based on the assumption that PCa volume 
correlates with PSA [128]. The PSA increase with time, that is PSADT, then reflects tu-
mour activity. In the prospective study Choo et al. defined disease progression based on 
repeat prostate needle biopsies, clinical progression and PSADT [122]. They arbitrarily 
used a PSADT less than 2 years as a criterion for treatment. In the current study 5 males 
had PSADT less than two years, of whom 4 changed therapy.
Furthermore they found that 42% of males (72) had PSADT greater than 10 years, sug-
gesting slowly progressive tumours [122]. When calculating PSA slope, we found a nega-
tive slope in 35 of 120 men (29.1%)(table 3). Because PCa is by definition a progressive 
disease, this remarkable finding, which has also been described by others [207], should 
be interpreted rather as result of the natural or biochemical variation of PSA [205, 208]. 
This phenomenon can also be explained by assay variation and, therefore, it most likely 
represents stable or minimally progressive PCa. A third explanation could be that with 
time PCa is dedifferentiating and produces less PSA. However, this seems less likely since 
most males in this study had favourable PCa characteristics at diagnosis. The finding that 
25 of 35 patients had a negative slope of –0.2 to 0 ng/mL yearly, corresponding with 
a PSA half-life of greater than 5 years, is in line with reported biological PSA variation 
[208]. In this study 30 patients (25%) had PSADT greater than 10 years, thus, suggesting 
indolent disease, which increases to 54.1% when the 35 with a negative slope are added 
to this group. This value is higher than the findings of Choo et al. [122]. However, they 
did not describe a subgroup with a decreasing PSA with time also, when comparing 
mean PSA slope and PSADT in patients with and without subsequent treatment, PSADT 
was significantly higher in those receiving subsequent treatment (p=0.006) (table 5). 
Several aspects must be considered when interpreting these results. 1) Study follow-
up is too limited to show differences in outcome after deferred treatment with curative 
intent. 2) Because follow-up is done at different centers, various PSA assays were used. 
Although regression equations to correct for assay type were used to calculate PSA 
change with time, we still found a wide interpatient range of PSA slope and PSADT. In 
a further attempt to minimize this variation we calculated PSA slope and PSADT while 
excluding the PSA value at diagnosis, without using the regression equations, assuming 
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that during follow-up the same assay was used. Of the 96 males with 3 or more PSA tests 
before treatment change in this subgroup 24 (25%) still had a decreasing PSA slope and 
19 (18.7%) had PSADT greater than 10 years. This finding is more in line with the findings 
of Choo et al. [122], and it again supports the possibility that there is a group of patients 
with favourable PCa characteristics that has slow progressive or even latent disease. 3) 
These patients were selected from 2 subsequent rounds of a PCa detection program and 
might not resemble an average population. However, as PSA driven screening becomes 
more prevalent in western countries, more males with comparable favourable PCa char-
acteristics will also be detected outside of a screen program.
The results of this study show that at least in screening detected PCa there is an iden-
tifiable population of males who have stable or even decreasing PSA with time. These 
patients could possibly benefit from a watchful waiting policy with possible deferred 
therapy at a later time. Further analyses of these data with longer follow-up could aid 
in coming to an evidence-based decision, justifying a watchful waiting policy with pos-
sible deferred treatment in select patients. Objective clinical parameters, such as PSA 
slope or PSADT activity, may be useful indicators for monitoring PCa. 
ConCLusIons
Watchful Waiting remains a controversial topic in prostate cancer treatment. However, in 
carefully selected screening detected patients with PCa it appears safe to delay curative 
treatment or even refrain from treatment. Together with conventional tumour param-
eters at diagnosis PSADT or PSA slope could be used to monitor tumour activity dur-
ing follow-up and possibly aid in determining the time of deferred treatment. Further 
follow-up is mandatory to validate these results. 
Conja Franken-Raab provided follow-up data. 
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appendix. Regression equations converting used PSA assay values into Hybritec 
Tandem-E values [204, 205].
y (Elecsys) = 1.03(Tandem E) - 0.02
y (Immulite) = 0.99(Tandem E) - 0.19
y (Access) = 1.03(Tandem E) - 0.08
y (IMx) = 0.89(Access) +0.01 Until Februari 1998 another reagent was used and no re-
gression equation available for the Tandem-E assay.
y (Tandem E) = 1.09(IMx) -0.06
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The goal of this thesis is to contribute to the evaluation of active surveillance (AS) as a 
safe strategy in selected men with organ confined prostate cancer (PCa) at diagnosis. To 
investigate the feasibility of an AS policy the key questions in AS were addressed;
- Who are suitable candidates?
- How to select and monitor these men?
- When to treat these patients without compromising the chance of cure?
In the general discussion the outcomes of the previous chapters are evaluated and com-
pared with the current perspectives on AS because continuous progress has occurred in 
recent years in both the fields of prostate cancer and of active surveillance. 
RatIonaLe FoR aCtIVe suRVeILLanCe
The concept of AS is to avoid or delay unnecessary treatment, with its inherent side-
effects and costs, while preserving the window of cure in these patients. As explained in 
the introduction PCa screening is associated with a shift towards more favourable PCa 
characteristics at diagnosis, lead-time bias, lenght-time bias and overdiagnosis of PCa [4, 
65, 142]. Thus PCa is diagnosed at an earlier age, at a more favourable stage and will in 
some patients never develop into clinical disease. These findings triggered the develop-
ment of an AS protocol within the ERSPC, section Rotterdam [217]. Chapter 3 is the re-
sult of an inventory of the different protocols used at the time. The expression “watchful 
waiting” was originally chosen to describe this policy as no international consensus was 
yet reached how to describe such a pro-active monitoring policy. Nowadays, watchful 
waiting as used in this thesis is replaced by the term “active surveillance”[126]. Chapter 
3 stands at the beginning of the development of an AS regimen in the Rotterdam region 
and led to a first policy proposal in November 2003 at the Rotterdam Comprehensive 
Cancer Registration (IKR) meeting. After regional introduction, the policy proposal was 
published in the magazine of the Dutch Urological Association [218]. This proposal has 
evolved into an international prospective, observational study “Prostate Cancer Research 
International: Active Surveillance study”, (PRIAS, www.prias-project.org) [219, 220]. More 
detailed information on the multicentre PRIAS study and other AS research endeavours 
is provided further down.
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seLeCtInG PatIents FoR an aCtIVe suRVeILLanCe PoLICy
In chapter 4 the overall survival (OS) and disease specific survival (DSS) of screen 
detected PCa patients are compared to a non screened cohort [197]. After a median 
follow-up of 55 months the five year OS and DSS were 88.3% and 97.5% respectively in 
the screen cohort compared to a DSS of 82% in the cohort of men from the northern 
part of the Netherlands aged 60 to 75 years and diagnosed between 1996 and 1998. 
In the prevalence screen cohort 81.4% of the patients had organ-confined disease and 
45.4% had favourable prognostic PCa characteristics. PCa death after a median follow-
up of 55.1 months occurred almost exclusively in the group of men with poor prognostic 
characteristics and none of the patients on an expectant management policy died of 
PCa. This finding is helpful in selecting patients for AS in the future. Firstly, PCa death was 
very uncommon during the first five years especially in the favourable risk group of the 
screen cohort. Future AS candidates should thus be recruited using the characteristics 
of this group. Furthermore, screen detected cases had a better DSS compared to clini-
cally detected cases which may identify a healthy screenee bias. As candidates for an AS 
policy these men may benefit longer from avoiding the side-effects of active treatment. 
It also becomes clear from the limited number of PCa deaths in this prevalence screen 
detected cohort of prostate cancers that follow-up of long duration is necessary to 
validate any treatment modality for organ confined screen detected PCa.
aCtIVe suRVeILLanCe PoLICIes oVeR tIMe
Results of a prospective randomized controlled trial of AS in the current PSA screen era 
are not yet available, therefore level one evidence based criteria for selecting, monitor-
ing and timing deferred treatment in active surveillance are non existent. The identifi-
cation criteria most widely used for prostate cancers that may be considered clinically 
“non significant” were proposed more than ten years ago [150, 221]. For example, the 
definition that clinically insignificant cancer should be smaller than 0.5 cc was suggested 
in 1993 [221]. It is based on 55 men (40%) out of 139 patients who had undergone a 
radical cystoprostatectomy for bladder cancer and had incidental PCa at pathological 
examination. 80% of these cancers were smaller than 0.5 cc and were classified as clini-
cally insignificant on the basis of epidemiological considerations. Another commonly 
used definition to predict insignificant cancer based on biopsy results and PSA density 
was introduced in 1994 [150]. Though this definition has been successfully tested with 
surgical specimens [222, 223] no validation study correlating biopsy outcome with the 
natural history of PCa is currently available. 
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tabLe 1
Choo.et al[122, 
228, 232]
Vd Berg et al.[227] Soloway et al. [229] Carter et al.[230]
Study type Prospective, 
single centre 
cohort since 
1995
Retrospective 
validation
Retrospective single centre 
cohort
1992-2007
Prospective longitudinal single 
centre cohort since 1995-2006
Number of 
patients
331 616 99 407
Mean follow-up 8 yr (2-11) 4.3 yr (0-11) 3.7 yr (1-14) 3.4 yr (0.2-12)
Region Toronto Canada ERSPC centers The 
Netherlands, Sweden 
and Finland
Miami, USA Baltimore, USA
Inclusion criteria PSA in 
ng/ mL
≤10 (≤ 15)* ≤10 ≤ 15 Mean 5 (range 0.3-24)
T Stage T1C-T2A T1C-T2 ≤T2 T1C
PSAD in 
ng/ml/
cc
Not used ≤ 0.2 Not used ≤ 0.15
Prostate biopsy 
characteristics
Gleason 
Score
≤ 3+3 (3+4)* ≤ 3+3
≤ 2 positive cores
≤ 3+3
≤ 2 positive cores, max 50% 
invasion
≤ 3+3
≤ 2 positive cores, max 50% 
invasion
Follow-up PSA, DRE 
3-monthly, after 
2 yrs 6-monthly
Varying per centre PSA, DRE 3-monthly, after 2 yrs 
6-monthly
PSA, FPSA, DRE 6 monthly
Repeat 
biopsy
After 1 year 
and 3-5 yearly 
thereafter
Not predefined After 6-12 mths and on clinical 
suspection thereafter
Yearly
Indications for 
treatment
Patient wish 
(10%)
 PSADT <3 yr 
(20%) 
Grade 
progression (5%)
Patient wish 
PSADT ≤ 3 yr
PSA > 10
Stage progression
Patient wish
PSADT (no predefined cutoff)
Grade progression 
Stage progression
Patient wish
Grade progression
> 50% of PCa invasion in a 
single biopsy core
Progression 
after deferred 
treatment (DT)
3 cases died 
of PCa despite 
deferred RP 
within a year of 
diagnosis
12% PSA failure (13 of 
159 cases 7/81 after RP
6/78 after RT
0/2 RP Thus no progression
0/3 RT
0/3 HT
Not available, though 2 men 
had lymph node involvement 
at deferred RP
%DT 35% (n= 101) 55% at 10 yr 8% (n= 8) 25% (n=103)
Without DT** Not available 43% at 10 yr 85% at 5 yr 59% at 3.4 yr
Disease specific 
survival
99% (n=3) 10 yr 100% 100% 100%
Overall survival 85% 10 yr 77% Not available 98%
Remarks AS appears to be 
safe in selected 
men 
110 of 197 men with 
DT had favourable PCa 
characteristics at the 
time of DT
In 65% initial repeat biopsy 
revealed no PCa. AS appears to 
be safe in selected men without 
compromising curability
20% of pt with deferred RP had 
adverse pathological findings 
but this is consistent with 
patients immediately treated.
[293]
DT not based on PSA kinetics or 
stage progression
* if age over 70 years at diagnosis
** excluding those patients lost to follow-up or withdrawn from the study
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Since the arbitrarily defined criteria for selection, follow-up and deferred treatment 
provided in chapter 3, numerous studies have appeared [122, 224-231]. Table 1 shows a 
selection of the key AS studies and their outcomes thus far.
The median follow-up of the first prospective protocol-based report on AS [122] cur-
rently amounts to about 8 years [228, 232]. The DSS of the 331 men on AS was 99.3%. 
Three men died of PCa; all had deferred treatment within a year of diagnosis due to 
rapid rise in PSA levels and developed bone metastasis in the same year of treatment, 
succumbing to the disease within 5.5 years after diagnosis. The overall survival was 85% 
and 35% received deferred treatment [228, 232].
A report combining data from different ERSPC centres showed that at a median 
follow-up of 4.3 years, none of the 616 men with favourable PCa initially managed on 
a AS policy died of PCa and 32% received deferred treatment [227]. Extrapolating the 
results to ten years after diagnosis, the DSS still was 100%, with a corresponding OS of 
77% and 43% of the patients continuing on AS. 13 out of 159 males (12.2%) treated with 
curative intent have biochemical recurrence of disease. One patient died of PCa 11 years 
after diagnosis and one man did develop metastases despite deferred RT within a year 
of diagnosis.
Soloway et al. report that out of 99 patients on AS 8 had deferred treatment and none 
of these men had evidence of biochemical recurrence at a three years of follow-up after 
treatment [229]. No patient died of PCa and 85% of the men continued on AS after five 
years. 63% of the patients had an initial 10 core repeat biopsy 6 to 12 months after diag-
nosis which showed no evidence of PCa at pathological examination in 65% of the men. 
During follow-up of these males with undetectable disease subsequent repeat biopsies 
demonstrated a Gleason score of 3+3 or greater in 25%, including two patients with a 
Gleason score of 3+4. 
Experience with AS at the Johns Hopkins Institute again shows 100% DSS with a 
probability of remaining on AS after 8 years of 49%, the OS was not reported [230]. Two 
patients had lymph node invasion at RP more than five years after diagnosis and 20% of 
49 men undergoing a deferred RP had adverse pathological characteristics correspond-
ing with a risk of 25% or more of biochemical recurrence at 10 years of follow-up.
Other active surveillance reports show similar excellent disease specific mortality 
ranging from 99% to 100% with follow-up ranging from three to seven years for patients 
with favourable disease [231, 233-237]. The follow-up periods are clearly too short to 
apply final judgement.
As appears from the data just reviewed, most inclusion criteria suggested in chapter 3 
remain unchanged. For example, most investigators still select PCa patients with clinical 
stage T1C or T2A with a Gleason score of 3+3 or less for AS [219, 234, 238]. However, the 
maximum level of PSA at diagnosis is now commonly extended to 10 ng/mL in com-
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parison to 5-8 ng/mL as proposed in chapter 3. Likewise, a tendency towards accepting 
two cores with PCa invasion as long as less than half of that cores is invaded with PCa 
and accepting a PSAD of 0.15 to 0.2 ng/mL/cc compared to 0.1 ng/mL/cc can be seen 
[219, 224, 226, 229, 230]. The main pitfalls of all the reports on AS is that none of the 
reported studies has a prospective randomized design and that follow-up is relatively 
short, especially if a lead-time of approximately 10 years associated with PCa screening 
[4, 239] is considered. 
CoMPaRInG tReatMent MoDaLItIes
Men eligible for an AS policy should be selected among the patients with favourable 
PCa characteristics as indicated above. While the ERSPC is not designed to compare 
treatment modalities several studies have attempted to compare the results of different 
treatments for localized prostate cancer [104, 109, 240-243].
Only the Scandinavian Prostate Cancer Group Study 4 (SPCG-4) study is a prospectively 
randomized study and shows a small though statistically significant advantage in DSS 
and OS for clinically detected patients treated with RP compared to patients treated with 
expectant management and palliative hormonal therapy after 12 years of follow-up as 
discussed in the introduction [109]. The Prostate cancer Intervention Versus Observation 
Trial (PIVOT) has just published its baseline results from 731 men recruited from 1994 
till 2002 [120]. Like the SPCG-4 study it is designed to compare surgery and watchful 
waiting defined as deferred palliative treatment. In the PIVOT trial 76% of men had a 
PSA driven PCa diagnosis compared to 5% in the Swedish study. In the PIVOT trial more 
men had a lower PSA and well differentiated disease (25% versus 13%) at diagnosis. First 
results are expected in 2010
Though currently no data are available comparing treatment related outcome in pa-
tients with only favourable screen detected PCa, prospectively randomized controlled 
trials have been initiated. In the United Kingdom the multicenter Prostate Testing for 
Cancer and Treatment (ProtecT) study has started in September 2001. The ProtecT study 
aims to evaluate the effectiveness, cost-effectiveness and acceptability of different treat-
ments for men with localised prostate cancer. The three treatments are active surveil-
lance, radical prostatectomy and external beam radiotherapy. The major objective will 
be to assess survival at 5, 10 and 15 years following treatment [244]. The Surveillance 
Therapy Against Radical Treatment (START) trial will also only include men with favour-
able PCa and is designed to compare outcome for AS against surgery, external beam 
radiation or brachytherapy. This study is still in the feasibility phase [120, 200, 239], but 
aims to enroll and follow 2,130 newly diagnosed patients with low-risk prostate cancer 
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in Canada, the U.S.A., England, and Europe. Results of these trials will undoubtedly 
hugely improve knowledge on selection, monitoring and timing of deferred treatment. 
IMPRoVInG seLeCtIon CRIteRIa
While the results of prospective randomized trials comparing AS to immediate treat-
ment with curative intent mature, patients, in current-day practice, need to be advised 
on treatment decisions right away. Together with the clinical stage, PSA level and 
prostatic volume, prostatic biopsy characteristics can be used in nomograms to predict 
whether a cancer will be indolent [127, 245-250].While these nomograms are currently 
the best we have, they still define an indolent cancer as an index tumour of smaller than 
0.5 cc with no Gleason pattern four or five based on data from the early nineties [221]. 
Using a nomogram one should appreciate the fact that up to 20% of cases are wrongly 
being classified as having indolent disease despite a predictive accuracy of 80 to 90% for 
having indolent cancer [127, 251].
Another, more user friendly tool, is the Cancer of the Prostate Risk Assessment (CAPRA) 
score [252]. It was originally designed to improve pre-treatment risk assessment. The 
CAPRA score was initially tested in patients treated with RP [252] and it has been ex-
ternally validated [253-255], The CAPRA ranges from 0 to 10 points and a higher score 
predicts a higher risk of recurrence of PCa. The score is based on PSA level, primary and 
secondary Gleason pattern, age, tumour stage, and percentage of biopsy cores invaded 
by PCa. In June 2009, the CAPRA score was successfully tested to predict clinical end-
points as development of metastasis, DSS and OS for patients with localized PCa treated 
with surgery, radiation therapy, AS or expectative management, making it a useful tool 
for current-day practice [91]. For a man with CAPRA score 1 this resulted in an estimated 
10 year metastasis free survival, DSS and OS of 99%, 98.2% and 76.7%, respectively. 
The keys to success for AS are parameters that can accurately identify and monitor 
indolent disease. Otherwise a patient with organ-confined disease at diagnosis might 
progress to metastasized disease while being on an AS with only palliative treatment 
remaining. Or even better, a marker or algorithm which avoids screening and diagnosis 
in potentially indolent PCa could dramatically enhance the effectivity of population 
based screening which currently has to cope with overdiagnosis. In the still continu-
ing quest for such a “holy grail”, precursor PSA (pPSA) was investigated in chapter 5 
Though groups were arbitrarily defined and on contrary ends of the PCa characteristics 
spectrum, combination of pPSA forms and %freePSA were able to predict a PCa with 
favourable characteristics in 77.3% [256]. Since then major steps in development have 
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been made. A fully automated though still research only [-2]pPSA assay has been 
developed and tested [257, 258]. Moreover, when analysing sera of patients with and 
without PCa, the authors found that incorporating %[-2]pPSA, %pPSA, total PSA and age 
in an artificial neural network delivered an area under the curve (AUC) of 0.84 with 95% 
confidence intervals of 0.80-0.87 compared to an AUC of 0.56 (0.51-0.61) for total PSA 
[257]. A neural network is a non-linear statistical data-modelling tool, which can be used 
to model complex relationships between inputs and outputs. However, the authors did 
not consider in this comparison the fact that most PCa are diagnosed through elevated 
PSA values, and that therefore the ROC analysis is subject to attribution bias. In this 
neural network, contrary to earlier reports [259, 260], the digital rectal examination and 
the prostatic volume, which are more subjective parameters, did not improve the AUC 
and were therefore omitted. Another report using data from both the ERSPC, section 
Rotterdam as well as the university of Innsbruck showed that %[-2]pPSA at 95% sensitiv-
ity reached a 22% specificity compared to 9% for %FPSA and tPSA within the tPSA range 
of 2-10 ng/mL [261]. Furthermore, %[-2]pPSA showed greater selectivity for detecting 
more aggressive cancers within the tPSA range of 4-10 ng/mL [261].
These promising findings based only on objective measurable serum values will lead 
to the release of an automated multiplex precursor PSA assay in the third quarter of 
2009 (personal communication Claude Darte from Beckman Coulter®). This will allow 
the validation and further exploration of these markers in randomized trials and might 
even establish the use of %pPSA in predicting dedifferentiation of PCa in patients on AS. 
Several other biomarkers for PCa detection and management are under evaluation [262-
264]. One study suggests that early prostate cancer antigen 2 (EPCA-2) has an equal or 
higher sensitivity for PCa detection but a statistically significantly better specificity than 
PSA. Moreover EPCA-2 appeared able to differentiate between organ and non-organ 
confined disease [265]. Likewise human glandular kallikrein 2 (hK2) [266, 267], prostate 
secretory protein 94 (PSP94) [268] prostate stem cell antigen (PSCA) [269, 270] amongst 
others [271, 272] may be able to differentiate between aggressive and relatively favour-
able PCa some even in PSA ranges lower than 10 ng/mL. As not all investigators found 
these promising results [273], and groups were still small future randomized trials are 
needed to show which markers are safe for selection of patients. 
In the new field of metabolomics, in which all small molecule metabolites within a 
biological sample are evaluated, a metabolite called sarcosine has received atten-
tion [274]. Sarcosine levels were immeasurable in benign prostatic tissue, elevated in 
prostate cancer tissue but significantly increased in patients with metastasized PCa. In 
a limited validation set of urines sarcosine was measurable in urine and differentiated 
“benign” biopsies from patients with biopsy proven PCa. While sarcosine might thus be a 
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marker for aggressive prostate cancer the authors also suggest that it could provide new 
leads for monitoring and targeted treatment strategies as sarcosine and its regulatory 
enzymes seem to modulate PCa progression. While sarcosine is still far away from any 
clinical utility the PCA3 urine test only introduced in 2003 is currently available for PCa 
detection after initially negative biopsies and investigated for its possible prognostic 
use [275, 276]. Moreover, PCA3 is independent of prostatic volume, serum PSA and prior 
negative biopsies and could be used in a nomogram to improve prediction of biopsy 
outcome [277]. In the effort to improve test characteristics PCA3 was sucesfully com-
bined with the prostate-specific and androgen regulated transmebrane protease-serine 
fusion transcript (TMPRSS2-ERG) in urinary sediments [278]. In a cohort of 78 men with 
biopsy proven PCa, the PCA3 test alone was positive in 48 urine samples, thus reaching 
a sensitivity of 62%, which improved to 73% in combination with the TMPRSS2-ERG test, 
without compromising specificity. Though this was a first feasibility study to combine 
these new markers others have also shown improvement of test results with multiplex 
assays combining several tests [264, 279], which in the future might even be used to 
predict a positive prostate biopsy outcome and tumour characteristics.
MonItoRInG DIsease
In chapter 6 PSA measurements over time are evaluated as a possible tool for monitor-
ing patients on an active surveillance policy. Sixty-five men (54.4%) had a stable or even 
slightly declining PSA with time suggesting indolent PCa [217]. In the Swedish section of 
the ERSPC only men with a PSA doubling time (PSADT) of four years or faster during their 
active surveillance experienced a PSA relapse after deferred treatment with a radical 
prostatectomy [280]. Few other reports have been published relating other outcomes 
observed in AS patients to PSA kinetics in screen detected prostate cancer [235, 281].
However fast rising PSA levels, mostly defined as a PSA velocity (PSAV) of 2 ng/mL/year 
in the year before surgery or radiotherapy, were significant predictors for biochemical 
relapse or disease specific mortality [282-284]. Sengupta et al. showed in a retrospective 
cohort of over two thousand men treated with surgery for PCa that pre-treatment PSAV 
was a better predictor of biochemical progression, while PSADT was a stronger predictor 
of clinical progression and death from PCa [285].
In the Baltimore Longitudinal Study of Aging PSAV did while PSADT did not correlate 
with high risk or fatal disease in a statistically significant fashion [286]. Another report 
showed that PSAV was a better predictor than PSADT for adverse pathological findings at 
repeat prostatic biopsy in men with untreated PCa [287]. Though both were statistically 
significant predictors, the area under the receiver-operating curve was 0.70 for PSAV and 
General discussion 107
7
0.63 for PSADT. Other reports showed no relation of PSAV or PSADT with outcome [177, 
288, 289].
The usefulness of PSADT as a predictive marker after therapy is illustrated by the fact 
that a workgroup has published suggestions how to report on PSADT data [290]. No 
such uniformity has yet been reached for active surveillance strategies. Most AS pro-
tocols suggest that PSADT greater than ten years or declining PSA over time reflects a 
good prognosis [122, 123, 219, 291]. Likewise, these ongoing AS strategies consider a 
PSADT faster than two to four years an indication for deferred treatment or at least for a 
repeat prostatic biopsy. To calculate PSADT is more difficult than to calculate PSAV, but a 
number of free of charge web based calculators exist that compute PSADT. In the PRIAS 
study such a tool is integrated and automatically provides PSADT. Evaluation of data of 
the PRIAS and other AS protocols will clarify the definitive role of PSADT and PSAV in AS.
saFety oF aCtIVe suRVeILLanCe
The chance of losing the window of cure during AS appears to be small, but AS is not 
a rose without thorns. As described in the section AS policies over time, the risk of 
biochemical recurrence of disease after deferred treatment is small and ranges from 0 
to 20% [227, 228, 230, 292]. The number of 20% is based on the pathological features 
of patient with deferred RP [230, 293]. This group presumes that males with a Gleason 
score of 4+3 or higher, pathological stage T3, positive surgical margins or nodal involve-
ment will have less than 75% probability of remaining free of biochemical recurrence 
10 years after surgery and should be considered having non curable PCa. A report from 
the same group investigating the effect of deferred therapy compared to immediate 
treatment with curative intent showed that delayed therapy did not compromise cur-
ability [293]. Though this result is of great value in the decision process whether or not 
to embark on an AS policy at the same time it shows that 20 to 23% [230, 293] of men 
eligible for an AS policy had these adverse finding at surgery indicating the need for 
better selection criteria. Other reports concur with the finding that deferred treatment 
does not alter disease specific outcome [280, 289, 294]. Out of 80 patients on AS at the 
Royal Marsden institute followed for 42 months on average, none of the 11 patients with 
deferred treatment had signs of biochemical recurrence of PCa with a median follow-up 
of 20 months after treatment. Furthermore no patient had yet developed metastasis or 
started on palliative hormonal treatment [292]. 
When combining the data on outcome of AS in the current PSA era, it appears to be 
safe at least in the short term for the majority of males and deferred treatment is not 
associated with deterioration of PCa prognosis. Considering the long natural history of 
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PCa in the groups of men selected for AS, long term observations are mandatory to 
allow final judgement.
aCtIVe suRVeILLanCe anD PRostate CanCeR sCReenInG
The ERSPC with over 250,000 recruited men in eight different countries and the Prostate, 
Lung, Colorectal, and Ovarian Cancer Screening Trial (PLCO) in the USA with 76,705 
men are evaluating the effect of screening with PSA and digital rectal examination on 
prostate cancer specific mortality [181, 295]. In March, 2009 the ERSPC group showed 
a statistically significantly 20% relative mortality reduction at a third interim analysis 
based on the predefined core group of over 160,000 men aged between 55 and 69 years 
in favour of the intervention arm [296]. During a median follow-up of nine years, 5,990 
cases of PCa (8.2%) were detected and 214 (0.29%) men died of the disease in the screen 
cohort. In the control arm 4,307 (4.8%) cases were diagnosed with PCa and 326 (0.37%) 
men succumbed to PCa, resulting in a statistically significant absolute reduction of 0.71 
PCa deaths per 1,000 men in favour of screening in the intention to screen analysis. Or 
put in another way 1,410 men needed to be screened to prevent one prostate cancer 
death, with an average of 1.7 screening visits within a nine-year period. Screening 
however increased prostate cancer incidence with 34 per 1,000 men so that 48 men 
(1,410/1,000x34) need to be treated to prevent one prostate cancer death at nine years 
of follow-up.
The PLCO study with over 38,000 men in the screen arm between the age of 55 to 74 
years and a median follow-up of 11.5 years was published at the same time because of 
continuing lack of a significance of the death rate between the two arms and informa-
tion suggesting harm from screening [297]. At ten years of follow-up 3,452 (9.0%) men 
were diagnosed with and 92 died of PCa in the intervention arm. The numbers of the 
control group were 2,974 (7.8%) and 82 respectively resulting in a relative rate ratio 
(death rate of the screen group divided by the death rate in the control group) of 1.11 
(95% confidence interval 0.83-150), implying a non-statistically significantly increase in 
prostate cancer mortality in the intervention arm [297].
These contradictory results can possibly be explained by differences in trial protocol 
[88, 298], selection bias, geographical differences [88] [299], compliance rates and PSA 
testing outside the trial [192, 298, 300-302], however this lies beyond the scope of this 
thesis.
An important result for AS is the confirmation in both studies that death was relatively 
uncommon during follow-up, with rates of PCa deaths per 10,000 person years of 2.0 
for the screen arm and 1.7 for the control group in the PLCO study at seven years. In 
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the ERSPC trial these numbers varied from 1.9 to 5.8 for the men aged 55 to 69 yr in the 
screen arm and 2.5 to 7.9 in the control group. This again confirms the relatively indolent 
natural course of many screen detected PCa. Together with the knowledge that
- patients with screen detected prostate cancer have a significantly higher chance 
(49%) of harbouring clinically insignificant cancer compared to clinically diagnosed 
males (13%) [127];
- the chance of having insignificant PCa rises at a subsequent screen [300, 303] trans-
lating into more favourable PCa characteristics [236, 304];
- patients diagnosed with PCa after a previous negative screen have a better outcome 
compared to men diagnosed at a prevalence screen even after correcting for T stage, 
Gleason score and initial PSA level [305]; 
- currently, in the USA, 91% of diagnosed PCa is organ confined, the vast majority 
has PSA driven diagnosed, non palpable, PCa with a small focus well differentiated 
Gleason sum 3+3 PCa and a PSA level of 10 ng/mL or less, with an associated relative 
5 year disease specific survival of 100% [69, 306]; 
- the ERSPC has a calculated 54% overdiagnosis rate with an associated lead-time of 
10.3 years [4], and approximately one third of the screen detected cancers can be 
identified as potentially indolent with the use of nomograms based on clinical an 
pathological characteristics [280, 303]; 
- other series reported overdiagnosis rates of 7- 93% and lead-times ranging from 
5 to 14.1 years with the longest lead-times for young men with well differentiated 
disease and the highest overdiagnosis rates for older men [94, 95, 100, 101, 307].
This can cumulate into an enormous pool of possible future AS candidates, making 
both AS and taking positions on offering screening a top priority in the urological and 
oncological practice.
Clear-cut advise on whether and who to screen cannot yet be provided, as, despite its 
statistically significant results, the ERSPC trial does not yet warrant population based 
screening as several aspects like population coverage, overdiagnosis, quality of life, cost 
and cost effectiveness have not yet been taken into account. Still the mortality reduc-
tion of 20% in favour of prostate cancer screening will probably only further fuel the 
already widespread use of opportunistic PSA driven PCa screening. On the other hand, 
men aged 70 to 74 years did not seem to benefit from screening in the ERSPC in an 
exploratory analysis, suggesting that screening for PCa should not be advisable in these 
men. Most urological and oncological societies do agree with testing as long as it is 
a shared initiative between patient and physician and both the potential benefits and 
limitations of prostate cancer early detection are discussed in advance, with those who 
favour testing [70, 308-312].
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quaLIty oF LIFe
This thesis did not directly address health related quality of life (HRQoL) aspects. With AS 
one hopes to defer or even refrain from radical therapy for potentially indolent PCa and 
thus to avoid unnecessary treatment related side-effects. However, the patient and his 
relatives need to cope with living with untreated cancer. This anxiety is well reflected by 
the fact that 10 to 50% of the men on an AS policy desire deferred treatment despite of 
the absence of clinical or biochemical progression of the disease [228, 236]. 
One randomized trial from the SPCG-4 initially showed no difference in psychological 
distress comparing patients treated with RP to men treated with watchful waiting [119], 
though after 6 to 8 years of follow-up distress seemed to grow in the watchful wait-
ing group while it remained stable in the RP group even after filtering out patients on 
androgen deprivation [313]. Though a drawback of this study is that each man only once 
filled out an assessment where a longitudinal study would have been even better [314]. 
Another study also reported a difference in HRQoL between treatment groups over 
time with patients treated with RP performing best and those treated with radiation the 
worst leaving the patients on watchful waiting in between [315].
Though the reported data concerns clinically diagnosed patients on an expectant 
management strategy comparable effect on HRQoL are to be expected at longer follow-
up in AS men. Another report showed that lifestyle interventions improving overall 
health positively impact HRQoL, showing that both physician and patient can manage 
some of the uncertainty and anxiety associated with AS successfully [316]. This impor-
tant aspect of AS will have to play a role in the decision process of males considering AS. 
The PRIAS, ProtecT and START trials will all address and hopefully clarify HRQoL aspect in 
a contemporary cohort of men treated with AS in the future [200, 244, 317].
FutuRe PeRsPeCtIVes
In the light of the recent results from the ERSPC showing a favourable effect on PCa 
specific mortality in favour of PCa screening it is to be expected that more men will 
demand PSA testing from their general practitioner or urologist. Awareness education 
explaining the potential benefits and limitations of prostate cancer seems warranted 
for patients as well as first and second line physicians. In the mean time investigations 
will need to focus on finding and optimizing reliable tools to predict indolent cancer 
based on non-invasive procedures. This would greatly enhance screening for PCa by 
reducing the number of prostatic biopsies and ideally making the detection of indolent 
PCa an exception rather than the rule, leaving only those patients who could benefit 
from curative treatment in terms of increased disease survival. During this quest for “the 
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holy grail” screen protocols will have to be perfected. Research for markers that predict 
indolent PCa even before diagnosis and markers that can timely predict progression 
of disease hopefully will be identified. A grant of 7.5 million euro from the Center for 
Translational Molecular Medicine was assigned in August 2009 for this purpose to three 
Dutch University Medical Centres, with the Erasmus MC leading the investigations, will 
surely boost this area of research. In the meantime with increasing follow-up of the 
current active surveillance research endeavours the true nature of screen detected PCa 
managed on AS will have to show its true value. Time can only tell whether PCa on ac-
tive surveillance behaves as a dormant volcano not altering the natural course of life in 
patients or whether it will transform into an active volcano releasing a lava flow of PCa 
cells metastasizing into the human body without previously releasing detectable signals 
announcing activity.
In summary, active surveillance can provide a temporary refuge for both patients and 
physicians while the prostate cancer screening data matures into evidence based rec-
ommendations and tools to avoid screening in patients with indolent disease are being 
developed.
AS is still an evolving treatment modality but appears to be safe within the ERSPC in 
selected patients, though follow-up is still limited. There is a clear difference in PCa out-
come between screen detected and clinically diagnosed PCa, making screen detected 
PCa patients more apt candidates for an AS policy. PSA kinetics, such as PSA doubling 
time, can be useful to monitor patients and timing deferred treatment. New biomarkers 
like precursor PSA are being extensively investigated to enhance pre-treatment deci-
sion-making. Current ongoing trials such as the PRIAS-project will boost improvements 
in selection and monitoring criteria for active surveillance protocols. Active surveillance 
could avoid unnecessary treatment, with its inherent side-effects and costs, in a time 
of overdiagnosis and overtreatment due to PSA driven screening, while preserving the 
window of cure. However active surveillance is not a rose without thorns as the window 
of cure could be lost during follow-up. 
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Summary
The goal of this thesis is to contribute to the evaluation of active surveillance (AS) as a 
safe strategy in selected men with organ confined prostate cancer (PCa) at diagnosis. To 
investigate the feasibility of an AS policy the key questions in AS were addressed;
-  Who are suitable candidates?
-  How to select and monitor these men?
-  When to treat these patients without compromising the chance of cure?
The concept of AS is to avoid unnecessary treatment, with its inherent side-effects 
and costs, while preserving the window of cure in males with localized PCa. First the 
rationale of deferred treatment in a potential lethal disease is explained providing back-
ground information on the prostate, prostate specific antigen (PSA) and prostate cancer 
in the introduction. The window of opportunity for AS is provided by screening which 
forwards the diagnosis in time and causes a shift towards more favourable prostate 
cancer characteristics at time of diagnosis. Together with the known relatively latent 
natural history op PCa in most cases this leads to overdiagnosis. Overdiagnosis is the 
detection of asymptomatic PCa that would never have been detected clinically if PSA 
had not been used as a screening test. Due to the anatomical position of the prostate, 
treatment of PCA with curative intent is not without morbidity and even mortality. The 
goal of AS is to defer or even defy treatment for these men with overdiagnosed PCa 
while keeping the window of cure with a detailed follow-up regimen. Patients and physi-
cians however will have to realize that active surveillance is still an empiric therapy. An 
overview of different selection parameters and follow-up criteria together with trigger 
points to time deferred treatment is given in Chapter 3.
Chapter 4 shows overall and disease specific rates of males diagnosed with PCa in the 
first round of ERSPC, section Rotterdam. These data are compared to a cohort of Dutch 
males outside the screening program. It was shown that PCa slowly progresses in most 
screen detected PCa cases and that prostate cancer deaths were rare during a median 
follow-up of 55 months. PCa deaths, when present, were more common in the non 
screened cohort. In the ERSPC cohort only one patient, with favourable prognostic PCa 
characteristics died of prostate cancer due to peri-operative complications out of a total 
of 20 PCa deaths. 
No patient initially managed on an active surveillance policy died during follow-up. 
This study showed the differences in outcome of a screen versus non-screen cohort 
making screen detected patients more apt AS candidates. Moreover due to the limited 
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PCa deaths it becomes clear that extensive follow-up is mandatory to compare treat-
ment modalities in screen detected PCa patients.
In chapter 5 experimental blood tests i.e. precursor PSA forms, are evaluated as a possible 
future selection tool to improve selection of patients for an active surveillance policy. As 
prostate specific antigen (PSA) is prostate specific and not PCa specific precursor forms 
of PSA, which form a part of the free PSA, and the so called benign PSA are investigated 
whether they can enhance sensitivity and specificity in identifying or excluding suitable 
patients for an active surveillance regimen. Frozen serum of screen detected cases with 
arbitrarily defined relatively latent PCa and aggressive tumour characteristics was used 
to retrospectively measure precursor PSA and benign PSA. The combination of precur-
sor PSA and %free PSA in a multivariate analysis reached a very high sensitivity of 95.5% 
and a specificity of 82.4% but could be attributed to a difference in total PSA levels 
and prostatic volume in the two groups. In a subset of 30 patients normalized for PSA 
level and prostatic volume the combination of precursor PSA and %free PSA correctly 
identified 89.5% and 54.5% of the patients with relatively favourable and aggressive PCa 
characteristics respectively. 
In chapter 6 the natural course of PSA levels of ERSPC patients currently managed on 
an expectative management policy including patients on active surveillance and its 
value as a monitoring tool to time deferred treatment is addressed. The idea is that PSA 
measurements over time correlate with tumour characteristics and could be a useful 
monitoring tool in patients on AS. More than half of the 120 patients in whom PSA 
doubling time (PSADT) could be calculated had a PSADT of 10 years or longer or even 
declining PSA values over time suggesting indolent disease. Thus there seems to be a 
subset of men with screen detected prostate cancer who have stable or even declining 
PSA values over time who might be candidates for AS and PSADT could be used to moni-
tor these patients.
In the general discussion these selection, and monitoring criteria are put into perspec-
tive and compared to the latest developments in the field of AS research. The selection 
and monitoring criteria proposed in chapter 3 have generally remained stable though 
there is a tendency towards more liberal inclusion with regard to the PSA value at diag-
nosis and number of prostatic biopsy cores invaded with PCa. Prospective randomized 
controlled trials of AS comparing treatment modalities in screen detected PCa have been 
initiated. Results of these trials will undoubtedly hugely improve knowledge on selec-
tion, monitoring, timing of deferred treatment and the quality of life though follow-up 
will have to be extensive as PCa specific mortality is rare in patients with organ confined 
screen detected PCa. In the meantime AS as a treatment strategy for selected males 
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with organ confined PCa at diagnosis is gaining ground, indirectly showing that most 
clinicians and researchers believe it to be a safe treatment modality while the search for 
biomarkers optimizing selection of patients for AS or, even able to predict indolent PCa 
before diagnosis is ongoing. Moreover the contemporary results of AS cohorts do not 
show a deterioration of PCa prognosis in these men.
In conclusion, based on the current available evidence, active surveillance, though still 
an evolving treatment modality, seems to provide a safe temporary refuge for both pa-
tients and physicians while prostate cancer screening data mature into evidence based 
recommendations and tools to avoid screening in patients with indolent disease are 
being developed. 
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Samenvatting
Het doel van dit proefschrift is bij te dragen aan de ontwikkeling van een actief 
afwachtend beleid (active surveillance, AS), een van de behandelstrategieën van pros-
taatkanker. De idee van dit actief afwachtend beleid is onnodige behandeling, en de 
daarmee geassocieerde bijwerkingen te voorkomen. Daarnaast blijft door intensieve 
follow-up de mogelijkheid bestaan om, indien nodig, alsnog een behandeling met 
curatieve intentie te geven. 
Om de haalbaarheid van een actief afwachtend beleid te toetsen, zijn de volgende 
vragen onderzocht:
•	 Welke	patiënten	zijn	geschikt	voor	een	actief	afwachtend	beleid?
•	 Hoe	kunnen	deze	patiënten	geselecteerd	en	gevolgd	worden?
•	 Wanneer	is	uitgestelde	therapie	nodig	om	de	kans	op	genezing	te	behouden?
In het eerste deel is achtergrond informatie verstrekt over een actief afwachtend beleid. 
De rationale van een actief afwachtend beleid bij een potentieel dodelijke ziekte wordt 
uiteengezet in hoofdstuk 1. 
hoofdstuk 2 geeft informatie over de prostaat, het prostaat specifiek antigeen (PSA), 
prostaatkanker en de effecten van vroegopsporing naar prostaatkanker. Met vroegop-
sporing wordt de diagnose prostaatkanker niet alleen eerder gesteld maar ook veel 
vaker. Bovendien heeft een dergelijk gediagnosticeerde prostaatkanker vaak relatief 
gunstige kenmerken en in de meeste gevallen een indolent natuurlijke verloop. Door 
vroegopsporing worden echter ook prostaatkankers opgespoord die nooit klachten 
zullen veroorzaken. Deze detectie van asymptomatische prostaatkankers wordt over-
diagnose genoemd. Binnen de European Randomized Study of Screening for Prostate 
Cancer (ERSPC), sectie Rotterdam wordt geschat dat ongeveer de helft van alle gevon-
den prostaatkankers zeer waarschijnlijk nooit symptomen zal geven. Veel artsen en 
patiënten zullen mogelijk onnodig kiezen voor een behandeling met curatieve intentie. 
Deze overbehandeling geeft per definitie geen levensverlenging, maar heeft wel een 
risico op bijwerkingen. Het doel van AS is om, op een veilige manier, behandeling uit te 
stellen of wellicht overbodig te maken.
hoofdstuk 3 geeft een overzicht van de verschillende vormen van een actief afwachtend 
beleid. Allereerst wordt het verschil duidelijk gemaakt tussen een expectatief beleid met 
palliatieve therapie (expectant management) en een actief afwachtend beleid (active 
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surveillance). De criteria voor inclusie en vervolgen van patiënten voor een actief afwa-
chtend beleid worden besproken. Ook wordt behandeld wanneer alsnog uitgestelde 
therapie nodig is. Het hoofdstuk eindigt met een voorstel voor een actief afwachtend 
beleid. 
Het tweede deel gaat dieper in op de selectie criteria voor een actief afwachtend 
beleid. In hoofdstuk 4 is de overleving weergeven van 1014 mannen, die in de eerste 
ronde van de ERSPC zijn gediagnosticeerd met prostaatkanker. Deze gegevens worden 
vergeleken met een patiëntencohort buiten het vroegopsporings-programma. Met een 
mediane follow-up van 55 maanden wordt aangetoond dat prostaatkanker ontdekt 
door vroegopsporing in de meeste gevallen een langzaam progressieve ziekte is. De 
prostaatkankerspecifieke mortaliteit is gering, maar hoger in het cohort zonder vroe-
gopsporingsprogramma. In de studiegroep is één patiënt uit de groep met relatief 
gunstige prostaatkankerkenmerken door peri-operatieve complicaties overleden. 17 
van de in totaal 20 prostaatkanker sterfgevallen zijn patiënten met slechte prognost-
ische kenmerken bij diagnose. Niemand uit de AS groep is gedurende de studie periode 
overleden aan prostaatkanker. Dit onderzoek laat duidelijk de verschillen in overleving 
zien tussen mannen met vroegopgespoord en klinisch gedetecteerd prostaatkanker. 
Het verheldert ook waarom mannen gediagnosticeerd met prostaatkanker na vroegop-
sporing geschikter zijn voor AS. Daarnaast wordt duidelijk dat een langdurige follow-up 
noodzakelijk is gezien het indolente verloop van de meeste prostaatkankers ontdekt 
door vroegopsporing.
In hoofdstuk 5 worden experimentele bloedtesten geëvalueerd. Omdat PSA prosta-
atspecifiek en niet prostaatkankerspecifiek is worden biochemische voorlopervormen 
van PSA (pPSA) onderzocht om de sensitiviteit en specificiteit om inclusie criteria voor 
AS te verbeteren. Deze pPSA-vormen maken onderdeel uit van het vrij PSA evenals het 
zogenoemde “benigne” PSA. Voor dit onderzoek zijn patiënten geselecteerd met ofwel 
relatief gunstige ofwel zeer ongunstige prostaatkanker eigenschappen. De combinatie 
van de pPSA-vormen en het percentage vrij PSA bereikte, in een multivariate analyse, 
een sensitiviteit van 95.5% met een specificiteit van 82.4%. Deze indrukwekkende 
waarden kunnen echter ook veroorzaakt zijn door het verschil in PSA waarden tussen de 
twee groepen. Derhalve is een subanalyse gedaan van 30 mannen waarbij gecorrigeerd 
is voor de PSA waarde en het prostaatvolume. In deze subanalyse is de voorspellende 
waarde voor een relatief gunstige prostaatkanker 89.5% en 54.5% voor een agressieve 
prostaatkanker. Geconcludeerd kan worden dat deze experimentele bloedtesten 
weliswaar veelbelovend zijn, maar verder onderzoek nodig is.
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Het derde deel schetst de waarde van het beloop van PSA over een periode van tijd, de 
PSA verdubbelingstijd (PSADT). De gedachte hierachter is dat meerdere PSA metingen 
tijdens de follow-up de prostaatkankeractiviteit weerspiegelen en de PSADT gebruikt 
zou kunnen worden als leidraad. hoofdstuk 6 beschrijft 191 mannen die niet direct 
behandeld zijn voor hun prostaatkanker. Bij 120 patiënten kon een PSADT berekend 
worden. Meer dan de helft van deze groep heeft een PSADT van meer dan 10 jaar of zelfs 
een dalende PSA trend, hetgeen suggestief is voor indolent prostaatkanker. 30 mannen 
hebben alsnog therapie gekregen en 1 hiervan heeft aanwijzingen voor een oplopend 
PSA na behandeling. Tijdens de follow-up (mediaan 40 maanden) overleed geen enkele 
patiënt aan prostaatkanker. Er blijkt dus een subgroep van mannen met vroegopge-
spoord prostaatkanker te zijn die stabiele of zelfs afnemende PSA waarden hebben. 
Deze patiënten kunnen mogelijk voor AS in aanmerking komen en de PSADT lijkt een 
goed hulpmiddel om deze mannen te vervolgen of eventuele uitgestelde behandeling 
aan te bevelen.
In de discussie worden de verschillende selectie- en vervolgcriteria vergeleken met 
de huidige literatuur en in perspectief gezet met de laatste ontwikkelingen op het 
gebied van AS. Hieruit blijkt dat de geopperde selectiecriteria van hoofdstuk 3 over het 
algemeen in stand zijn gebleven. Er lijkt een tendens te bestaan naar het verhogen van 
de PSA waarde. Ook worden tegenwoordig patiënten geïncludeerd met meer dan één 
prostaatnaaldbiopt dat prostaatkanker bevat. Deze verruiming van de selectiecriteria 
heeft waarschijnlijk te maken met meer kennis omtrent het – in de meeste gevallen - 
indolente verloop van prostaatkanker ontdekt door vroegopsporing.
Prospectief gerandomiseerde onderzoeken, welke de verschillende behandelingen 
van vroegopgespoorde prostaatkanker (inclusief AS) gaan vergelijken, zijn geïnitieerd. 
Een van deze onderzoeken, de PRIAS (Prostate cancer Research International: Active 
Surveillance) studie (www.prias-project.org), is geëvolueerd uit een voorstel voor AS 
in de regio Rotterdam. De resultaten van deze onderzoeken zullen terdege bijdragen 
aan de kennis omtrent selectie, vervolgen en bepalen van het tijdstip van uitgestelde 
behandeling bij AS. Aan de andere kant zullen de definitieve resultaten pas na jaren be-
schikbaar zijn, gezien het indolente verloop in het merendeel van deze prostaatkankers. 
De meest recente resultaten van de ERSPC laten een significante daling van de prosta-
atkanker specifieke sterfte zien ten gunste van vroegopsporing. Derhalve zal, gezien de 
aan vroegopsporing gerelateerde overdiagnose, AS alleen maar actueler worden. 
Het blijkt dat AS als behandeling bij geselecteerde mannen met prostaatkanker ontdekt 
door vroegopsporing steeds vaker voorkomt. Dit laat indirect zien dat zowel onderzoek-
ers als clinici het een veilige behandeling vinden. Daarnaast laten de huidige resultaten 
van behandeling met AS geen verslechtering in prognose zien gedurende de follow-up. 
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Samenvattend is er een duidelijk verschil in prognose tussen klinisch gediagnosticeerd 
of na vroegopsporing ontdekt prostaatkanker. Vroegopgespoord prostaatkanker heeft 
een duidelijk betere ziekte-specifieke overleving. Op basis van de beschikbare literatuur, 
lijkt AS veilig voor geselecteerde mannen met prostaatkanker ontdekt door vroegop-
sporing. De zoektocht naar biomarkers, die de selectiecriteria voor AS verfijnen, het 
tijdstip van uitgestelde behandeling optimaliseren of, wellicht indolent prostaatkanker 
kunnen voorspellen voordat de diagnose gesteld wordt, is in volle gang. De resultaten 
van prospectieve studies zullen de definitieve waarde van AS aantonen terwijl de ge-
gevens van de effecten van vroegopsporing naar prostaatkanker uitkristalliseren. In de 
tussentijd kan AS, bij overgediagnosticeerd prostaatkanker, onnodige behandeling, en 
de daaraan gerelateerde ongewenste bijwerkingen en kosten, voorkomen. 
Zowel patiënten als behandelaars moeten zich bewust zijn het feit dat AS nog 
steeds een empirische behandeling is en dat gedurende een actief afwachtend beleid 
prostaatkanker van een slapende naar een actieve vulkaan kan transformeren en de 
mogelijkheid op genezing daarmee in rook is opgegaan. 
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